<SEC-DOCUMENT>0001193125-20-261322.txt : 20201001
<SEC-HEADER>0001193125-20-261322.hdr.sgml : 20201001
<ACCEPTANCE-DATETIME>20201001162121
ACCESSION NUMBER:		0001193125-20-261322
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20201001
DATE AS OF CHANGE:		20201001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Beam Therapeutics Inc.
		CENTRAL INDEX KEY:			0001745999
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-249093
		FILM NUMBER:		201216155

	BUSINESS ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-327-8775

	MAIL ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d14461d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to Rule 424(b)(4) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="2">Registration No. 333-249093 </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Prospectus </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><I>5,000,000 shares </I></B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g14461g85q17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="6"><B>Beam Therapeutics Inc. </B></FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I>Common stock </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are offering 5,000,000 shares of our
common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our common stock is listed on the Nasdaq Global Select Market (&#147;Nasdaq&#148;) under the symbol &#147;BEAM.&#148; The last reported
sale of our common stock on Nasdaq on September 25, 2020 was $26.76 per share. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an &#147;emerging growth company&#148; and a &#147;smaller
reporting company&#148; under federal securities laws and are subject to reduced public company reporting requirements. See &#147;Summary&#151;Implications of being an emerging growth company and smaller reporting company.&#148; </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Per&nbsp;share</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23.50</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">117,500,000.00</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Underwriting discounts and commissions(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.41</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,050,000.00</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds to Beam Therapeutics Inc., before expenses</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22.09</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">110,450,000.00</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See &#147;Underwriting&#148; for additional disclosure regarding underwriting compensation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have granted the underwriters an option for a period of 30 days to purchase up to 750,000 additional shares of common stock from us at the public offering price, less underwriting discounts and commissions.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Investing in our common stock involves a high degree of risk. See the section titled &#147;<A HREF="#rom14461_2">Risk factors</A>&#148; beginning on
page 18 of this prospectus. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of
these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
underwriters expect to deliver the shares to purchasers on or about October 5, 2020. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Joint bookrunning managers </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="5"><B>J.P. Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Jefferies</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Barclays</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Lead manager </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="4"><B>Wedbush PacGrow </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">September 30, 2020. </FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc"></A>Table of contents </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_1">Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_2">Risk factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_3">Special note regarding forward-looking statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_4">Use of proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_5">Dividend policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_6">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_7">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_8">Market price of our common stock </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_9">Principal stockholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_10">Description of capital stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_11">Material U.S. federal income tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our common
 stock </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_12">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_13">Legal matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_14">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_15">Where you can find additional information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom14461_16">Incorporation of certain information by reference</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Neither we nor the underwriters have authorized anyone to provide any information other than that contained or incorporated by
reference in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others
may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or incorporated by reference is
accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since
that date. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For investors outside of the United States: Neither we nor the underwriters have done anything that would permit this offering or possession
or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and
observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">i </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Trademarks </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:arial" SIZE="2">We use BEAM, REPAIR and RESCUE and other marks as trademarks in the United States and/or in other countries. This prospectus contains references to our trademarks and service marks and to those belonging to other
entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the
rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any
other entity. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Market and industry data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless
otherwise indicated, information contained in this prospectus or incorporated by reference concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our
management&#146;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. We believe that the information from these third-party publications, research, surveys and studies
included in this prospectus is reliable. Management&#146;s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable.
This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#147;Risk factors.&#148; These and other
factors could cause our future performance to differ materially from our assumptions and estimates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">ii </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_1"></A>Summary </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>This summary highlights information contained elsewhere in this prospectus or incorporated by reference into this prospectus from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
year ended December&nbsp;31, 2019, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
June&nbsp;30, 2020 and our other filings with the Securities and Exchange Commission (the &#147;SEC&#148;) listed in the section of this prospectus entitled &#147;Incorporation of certain information by reference&#148; and is qualified in its
entirety by the more detailed information and consolidated financial statements included or incorporated by reference elsewhere in this prospectus. This summary does not contain all of the information that may be important to you. You should read
and carefully consider the following summary together with the entire prospectus and the documents incorporated herein by reference, including our consolidated financial statements and the notes thereto incorporated herein by reference and the
matters discussed under the sections titled &#147;Risk factors,&#148; &#147;Selected financial data&#148; and &#147;management&#146;s discussion and analysis of financial condition and results of operations&#148; appearing elsewhere in this
prospectus, in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020,
or in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2020, each incorporated by reference herein, before deciding to invest in our common stock. Some of the statements in this prospectus
constitute forward-looking statements that involve risks and uncertainties. See &#147;Special note regarding forward-looking statements.&#148; Our actual results could differ materially from those anticipated in such forward-looking statements as a
result of certain factors, including those discussed in &#147;Risk factors&#148; and other sections of this prospectus and the documents incorporated herein by reference. </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Unless the context otherwise requires, the terms &#147;Beam,&#148; &#147;Beam Therapeutics,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; relate to Beam Therapeutics Inc.,
together with its consolidated subsidiaries. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Overview </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering
from serious diseases. Our proprietary base editing technology potentially enables an entirely new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. This approach uses a
chemical reaction designed to create precise, predictable and efficient genetic outcomes at the targeted sequence. Our novel base editors have two principal components: (i)&nbsp;a CRISPR protein, bound to a guide RNA, that leverages the established <FONT
STYLE="white-space:nowrap">DNA-targeting</FONT> ability of CRISPR, but modified to not cause a double-stranded break, and (ii)&nbsp;a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA
base. We believe this design contributes to a more precise and efficient edit compared to traditional gene editing methods, which operate by creating targeted double-stranded breaks in the DNA; these breaks can result in unwanted DNA modifications.
We believe that the precision of our editors will dramatically increase the impact of gene editing for a broad range of therapeutic applications. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To
unlock the full potential of our base editing technology across a wide range of therapeutic applications, we are pursuing a comprehensive suite of clinically validated delivery modalities in parallel. For a given tissue type, we use the delivery
modality with the most compelling biodistribution. Our programs are organized by delivery modality into three distinct pipelines: electroporation for efficient delivery to blood cells and immune cells <I>ex vivo</I>; lipid nanoparticles, or LNPs,
for <FONT STYLE="white-space:nowrap">non-viral</FONT> <I>in vivo</I> delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors, or AAV, for <I>in vivo</I> viral delivery to the eye and central nervous
system, or CNS. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">1 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The elegance of the base editing approach combined with a tissue specific delivery modality, provides the basis
for a targeted, efficient, precise, and highly versatile gene editing system, capable of gene correction, gene silencing/gene activation, and multiplex editing of several genes simultaneously. We are currently advancing a broad, diversified
portfolio of base editing programs against distinct editing targets, utilizing the full range of our development capabilities. We believe the flexibility and versatility of our base editors may lead to broad therapeutic applicability and
transformational potential for the field of precision genetic medicines. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We continue to make meaningful advancements across our programs. Within our
<I>ex vivo </I>platform, we have identified two development candidates to date: <FONT STYLE="white-space:nowrap">BEAM-101,</FONT> our program that reproduces single base changes seen in individuals with Hereditary Persistence of Fetal Hemoglobin, or
HPFH, to potentially protect them from the effects of mutations causing sickle cell disease or thalassemia, and <FONT STYLE="white-space:nowrap">BEAM-102,</FONT> our program to directly correct the causative mutation in sickle cell disease by
recreating a naturally-occurring normal human hemoglobin variant, <FONT STYLE="white-space:nowrap">Hb-G</FONT> Makassar. We have achieved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> <I>in vivo</I>
with long-term engraftment of base edited human CD34 cells in mice for <FONT STYLE="white-space:nowrap">BEAM-101.</FONT> Persistence of engraftment and high levels of editing have been confirmed in several studies, including in studies using
material generated at a clinically relevant scale. Following conversations with regulators and supported by our <FONT STYLE="white-space:nowrap">off-target</FONT> biology assays, we are planning to initiate
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in 2020 and expect to file an IND for <FONT STYLE="white-space:nowrap">BEAM-101</FONT> during the second half of 2021. During the second quarter of 2020, we also published data on <FONT
STYLE="white-space:nowrap">BEAM-102</FONT> demonstrating that our adenine base editors, or ABEs, can efficiently convert the causative Hemoglobin S, or HbS, point mutation, to the normal <FONT STYLE="white-space:nowrap">HbG-Makassar,</FONT> with
high efficiency (more than 80%). The Makassar variant does not cause hemoglobin to polymerize, or red cells to sickle and, therefore, edited cells are cured through elimination of the disease-causing protein. The results from this study confirmed
the ability of the Makassar variant to protect cells from sickling, even in the context of mono-allelic editing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are also progressing our cell
therapy programs in oncology, engineering <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells for pediatric leukemias with a high level of multiplex editing, and plan to publish data describing our editing targets and initial <I>in vivo </I>proof of
concept data during the fourth quarter of 2020. Additionally, we expect to nominate our first <FONT STYLE="white-space:nowrap">CAR-T</FONT> development candidate by <FONT STYLE="white-space:nowrap">year-end</FONT> 2020, bringing to three the number
of development candidates from our <I>ex vivo </I>portfolio. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also continue to advance our liver disease programs. During the second quarter of 2020,
we showed the ability to directly correct the mutation causing <FONT STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency, providing both <I>in vitro</I> and <I>in vivo</I> proof of concept for base editing to correct this disease. We
have also achieved editing levels, in preclinical models, for the correction of the two most prevalent mutations causing GSD1A disease that could be clinically relevant if reproduced in humans. An important next step for the liver disease programs
is finalizing our LNP formulation, and we are making progress on developing a formulation using proof of concept targets. To date, with this formulation, we have shown high levels of editing in mice at doses consistent with clinical use. We are
currently conducting <FONT STYLE="white-space:nowrap">non-human</FONT> primate studies to evaluate our LNP formulation and anticipate initial data in early 2021. We believe we are on track to nominate our first development candidate from our liver
portfolio in 2021. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">2 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our base editing platform </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g14461g07f07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The modularity of our platform means that establishing preclinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> of base editing using a particular delivery modality will potentially reduce risk and accelerate the timeline for additional product candidates that we may develop targeting the same tissue.
In some cases, a new product candidate may only require changing the guide RNA. Subsequent programs using the same delivery modality can also take advantage of shared capabilities and resources of earlier programs. In this way, we view each delivery
modality as its own unique pipeline, where the success of any one program may pave the way for a large number of additional programs to progress quickly to the clinic. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Ex vivo electroporation for hematology: sickle cell disease and beta-thalassemia </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Sickle cell disease, a severe
inherited blood disease, is caused by a single point mutation, E6V, in the beta globin gene. This mutation causes the mutated form of hemoglobin, or HbS, to aggregate into long, rigid molecules that bend red blood cells into a sickle shape under
conditions of low oxygen. Sickled cells obstruct blood vessels and die prematurely, ultimately resulting in anemia, severe pain (crises), infections, stroke, organ failure, and early death. Sickle cell disease is the most common inherited blood
disorder in the United States, affecting an estimated 100,000 individuals, of which a significant proportion are of African-American descent (1:365 births). Beta-thalassemia is another inherited blood disorder characterized by severe anemia caused
by reduced production of functional hemoglobin due to insufficient expression of the beta globin protein. Transfusion-dependent beta-thalassemia, or TDBT, is the most severe form of this disease, often requiring multiple transfusions per year.
Patients with TDBT suffer from failure to thrive, persistent infections, and life-threatening anemia. The incidence of symptomatic beta-thalassemia is estimated to be 1:100,000 worldwide, including 1:10,000 in Europe. In the United States, based on
affected birth incidence of 0.7 in 100,000 births, and increasing survival rates, we expect the population of individuals affected by this disease to be more than 1,400 and rising. The only potentially curative therapy currently available for
patients with sickle cell disease or beta-thalassemia is allogeneic Hematopoietic Stem Cell Transplant, or HSCT; however, this procedure holds a high level of risk, particularly Graft-versus-Host Disease, or GvHD, resulting in a low number of
patients opting for this treatment. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">3 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are using base editing to pursue two complementary approaches to treating sickle cell disease and one to treat
beta-thalassemia: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a differentiated approach to elevating fetal hemoglobin which could be used in treatments for both sickle cell disease and beta-thalassemia <FONT
STYLE="white-space:nowrap">(BEAM-101);</FONT> and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a novel approach to directly correcting the sickle mutation <FONT STYLE="white-space:nowrap">(BEAM-102).</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">BEAM-101:</FONT> Recreating naturally-occurring protective mutations to activate fetal hemoglobin </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The beneficial effects of the fetal form of hemoglobin, or HbF, to compensate for mutations in adult hemoglobin were first identified in individuals with a
condition known as HPFH. Individuals who carry mutations that would have typically caused them to be beta-thalassemia or sickle cell disease patients, but who also have HPFH, are asymptomatic or experience a much milder form of their disease. HPFH
is caused by single base changes in the regulatory region of the genes, HBG1 and HBG2, which prevents binding of one or more repressor proteins and increases the expression of gamma globin, which forms part of the HbF tetramer. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Using base editing, we reproduce these specific, naturally occurring base changes in the regulatory elements of the gamma globin genes, preventing binding of
repressor proteins and leading to <FONT STYLE="white-space:nowrap">re-activation</FONT> of gamma globin expression, and thus the increase in gamma globin levels. Our in vitro and in vivo characterization of
<FONT STYLE="white-space:nowrap">BEAM-101</FONT> using ex vivo delivery achieved precise and efficient editing of human CD34&#043; hematopoietic stem and progenitor cells, or HSPCs, resulting in long-term engraftment and therapeutically-relevant
increases in target gene expression in mice. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>In vitro characterization of <FONT STYLE="white-space:nowrap">BEAM-101:</FONT> </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We demonstrated greater than 90% editing in healthy donor CD34 cells in vitro. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We demonstrated gamma globin upregulation following erythroid differentiation is highly correlated (R2&#061;0.993) with editing rates, where, at greater than 90%
editing, we achieve greater than 60% increase in gamma globin in healthy donor CD34&#043; cells. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Successful editing of CD34&#043; cells from a homozygous sickle cell disease patient, demonstrating a greater than 60% increase in gamma globin levels with a
concomitant decrease to less than 40% sickle beta globin levels in vitro after in vitro differentiation. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>In vivo performance of <FONT
STYLE="white-space:nowrap">BEAM-101:</FONT> </I></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We demonstrated that edited CD34&#043; cells from a healthy human donor engraft with high chimerism and maintain greater than 90% editing after 16 weeks in
immunocompromised mice. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We demonstrated after <FONT STYLE="white-space:nowrap">16-week</FONT> engraftment that base edited cells lead to successful multilineage reconstitution with
greater than 90% base editing achieved in sorted human HSPCs, myeloid, lymphoid and erythroid cells. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We replicated these findings with cells from a second donor at 18 weeks post-engraftment. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">BEAM-102:</FONT> Direct correction of the sickle cell mutation </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our second base editing approach for sickle cell disease, <FONT STYLE="white-space:nowrap">BEAM-102,</FONT> is a direct correction of the causative sickle mutation
at position 6 of the beta globin gene. By making a single <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A-to-G</FONT></FONT> edit, we have demonstrated in </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">4 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
primary human CD34&#043; cells isolated from sickle cell disease patients the ability to create the naturally occurring Makassar variant of hemoglobin. This variant, which was originally
identified in humans in 1970, has the same function as the wild-type variant and does not cause sickle cell disease. Distinct from other approaches, cells that are successfully edited in this way are fully corrected, no longer containing the sickle
protein. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">BEAM-102</FONT> uses ex vivo delivery of our adenine base editor, or ABE, to edit CD34&#043; HSPCs. In cells
isolated from donors with sickle cell disease, we achieved greater than 80% correction of the sickle point mutation to the <FONT STYLE="white-space:nowrap">HbG-Makassar</FONT> variant, following in vitro erythroid differentiation. As expected, we
observed the simultaneous reduction of HbS to less than 20% of control levels. More than 70% of erythroid colonies derived from edited patient cells showed biallelic editing (yielding cells that are potentially cured, no longer producing any sickle
protein at all) and another 20% of cells had monoallelic editing (with one sickle allele and one corrected allele, conferring a level of protection similar to patients with &#147;sickle cell trait&#148; who do not show significant symptoms of
disease) &#150; adding up to 93% of cells with potential elimination of sickle cell disease. Further, the correction of the HbS protein to the <FONT STYLE="white-space:nowrap">HbG-Makassar</FONT> variant was shown to significantly reduce the
propensity of in vitro differentiated erythroid cells to sickle when subjected to hypoxia. These findings represent therapeutic levels of correction and support advancement of this program to potentially address the underlying genetic cause of
sickle cell disease. Published modeling studies suggest that at least 20% of cells expressing HbF may be sufficient to cure the disease. With upregulation levels of more than 60% of gamma globin, we have shown, in preclinical models correction
levels significantly above these levels. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Ex vivo electroporation for multiplex editing: <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell
therapies for <FONT STYLE="white-space:nowrap">T-ALL/AML</FONT> </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe base editing is an ideal tool to simultaneously multiplex edit many
genes without unintended <FONT STYLE="white-space:nowrap">on-target</FONT> effects, such as genomic rearrangements or activation of the p53 pathway, that can result from simultaneous editing with nucleases through the creation of double strand
breaks. The ability to create a large number of multiplex edits in T cells could endow <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells and other cell therapies with combinations of features that may dramatically enhance their therapeutic
potential in treating hematological or solid tumors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Proof-of-concept</FONT></FONT>
experiments have now demonstrated the ability of base editors to efficiently modify up to 8 genomic loci simultaneously in primary human T cells with efficiencies ranging from <FONT STYLE="white-space:nowrap">85-95%</FONT> as measured by flow
cytometry of target protein knockdown. Importantly, these results are achieved without the generation of chromosomal rearrangements, as detected by a sensitive method (UDiTaSTM) and with no loss of cell viability from editing. The <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> experiments have also demonstrated robust T cell killing of target tumor cells. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our initial focus will be on hematologic malignancies, and we are developing allogeneic <FONT STYLE="white-space:nowrap">CAR-T</FONT> product candidates that have four edits each. This multiplex editing will enable
a high degree of engineering and functionality, including the following simultaneous edits: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Prevent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">graft-vs-host.</FONT></FONT> Elimination of the existing TCR to ensure that the <FONT
STYLE="white-space:nowrap">CAR-T</FONT> cell only attacks the CAR antigen on the tumor and not the patient&#146;s healthy cells. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Enable allogeneic cell source. Another edit to enable the use of healthy donor cells. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Minimize interference by the tumor microenvironment. An additional edit to minimize exhaustion by the T cell and prolong efficacy for attacking the tumor.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Prevent fratricide. Additional edits to eliminate antigens that are shared between malignant cells and <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells, to
prevent fratricide (i.e., <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells attacking each other before they can attack the tumor). </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">5 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The initial indications that we plan to target with these product candidates are relapsed, refractory, pediatric <FONT
STYLE="white-space:nowrap">T-cell</FONT> Acute Lymphoblastic Leukemia, or <FONT STYLE="white-space:nowrap">T-ALL,</FONT> and pediatric Acute Myeloid Leukemia, or AML. We believe that our approach has the potential to produce higher response rates
and deeper remissions than existing approaches. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><FONT STYLE="white-space:nowrap">Non-viral</FONT> delivery for liver diseases: <FONT
STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency and glycogen storage disorder 1a </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Alpha-1</FONT>
Antitrypsin Deficiency, or <FONT STYLE="white-space:nowrap">Alpha-1,</FONT> is a severe inherited genetic disorder that can cause progressive lung and liver disease. The most severe form of <FONT STYLE="white-space:nowrap">Alpha-1</FONT> arises when
a patient has a point mutation in both copies of the SERPINA1 gene at amino acid 342 position (E342K, also known as the PiZ mutation or the &#147;Z&#148; allele). This point mutation causes <FONT STYLE="white-space:nowrap">alpha-1</FONT>
antitrypsin, or AAT, to misfold, accumulating inside liver cells rather than being secreted, resulting in very low levels <FONT STYLE="white-space:nowrap">(10%-15%)</FONT> of circulating AAT. As a consequence, the lung is left unprotected from
neutrophil elastase, resulting in progressive, destructive changes in the lung, such as emphysema, which can result in the need for lung transplants. The mutant AAT protein also accumulates in the liver, causing liver inflammation and cirrhosis,
which can ultimately cause liver failure or cancer and require patients to undergo a liver transplant. It is estimated that approximately 60,000 individuals in the United States have two copies of the Z allele. There are currently no curative
treatments for patients with <FONT STYLE="white-space:nowrap">Alpha-1.</FONT> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">With the high efficiency and precision of our base editors, we aim to
utilize our ABEs to enable the programmable conversion of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A-to-T</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">G-to-C</FONT></FONT> base pairs
and precisely correct the E342K point mutation back to the wild type sequence. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For a recent study, we engineered novel ABEs and guide RNAs capable of
correcting the PiZ mutation, and then used a proprietary <FONT STYLE="white-space:nowrap">non-viral</FONT> lipid nanoparticle formulation to deliver the optimized reagents to the livers of a PiZ transgenic mouse model. This direct editing approach
resulted in an average of 16.9% correction of beneficial alleles at 7 days and 28.8% at three months. This significant increase over the period suggests that corrected hepatocytes may have a proliferative advantage relative to uncorrected cells. In
addition, treated mice demonstrate decreased <FONT STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin, or A1AT, globule burden within the liver and a durable, significant increase in serum A1AT active protein at three months, roughly <FONT
STYLE="white-space:nowrap">4.9-fold</FONT> higher than in controls, levels which we believe would be clinically relevant if achieved in patients. These data indicate the potential for base editing as a
<FONT STYLE="white-space:nowrap">one-time</FONT> therapy to treat both lung and liver manifestations of <FONT STYLE="white-space:nowrap">Alpha-1.</FONT> </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Glycogen Storage Disease Type 1A, also known as Von Gierke disease, is an inborn disorder of glucose metabolism caused by mutations in the G6PC gene, which results
in low blood glucose levels that can be fatal if patients do not adhere to a strict regimen of slow-release forms of glucose, administered every one to four hours (including overnight). There are no disease-modifying therapies available for patients
with GSD1a. Our approach to treating patients with glycogen storage disease 1a, or GSD1a, is to apply base editing via LNP delivery to repair the two most prevalent mutations that cause the disease, R83C and Q347X. It is estimated that these <FONT
STYLE="white-space:nowrap">two-point</FONT> mutations account for 900 and 500 patients, respectively, in the United States, representing approximately 59% of all GSD1a patients. Animal studies have shown that as little as 11% of normal G6Pase
activity in liver cells is sufficient to restore fasting glucose; however, this level must be maintained in order to preserve glucose control and alleviate other serious, and potentially fatal, GSD1a sequelae. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have identified product candidates that can correct up to 80% of the alleles in cells harboring the Q347X point mutation and approximately 60% of the alleles in
cells harboring the R83C mutation as shown in the </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">6 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
figures below. Correction of at least 11% is expected to be clinically relevant and potentially disease modifying for GSD1a patients. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Viral delivery for ocular and CNS disorders: Stargardt disease </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The most prevalent mutation in the ABCA4 gene
that leads to Stargardt disease is the G1961E point mutation. Approximately 5,500 individuals in the United States are affected by this mutation. Our base editing approach is to repair the G1961E point mutation in the ABCA4 gene. Disease modeling
using tiny spot stimuli, or light stimuli through holes that are equivalent in size to a single photoreceptor cell, suggests that only <FONT STYLE="white-space:nowrap">12%-20%</FONT> of these cells are sufficient to preserve vision. We anticipate,
therefore, that editing percentages in the range of <FONT STYLE="white-space:nowrap">12%-20%</FONT> of these cells would be disease-modifying, since each edited cell will be fully corrected and protected from the biochemical defect. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have identified a base editor that is able to edit approximately 45% of the alleles in recombinant cells carrying the human mutated sequence. Given that the base
editor is larger than the packaging capacity of a single AAV, we use a split AAV system that delivers the base editor via two AAV vectors. Once inside the cell, the two halves of the editor are recombined to create a functional base editor. In a
human retinal pigment epithelial cell line <FONT STYLE="white-space:nowrap">(ARPE-19</FONT> cells) in which we have knocked in the ABCA4 G1961E point mutation, we have demonstrated the precise correction of approximately 75% of the disease alleles
at 5 weeks after dual infection with the split AAV system. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Collaborations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We believe our base editing technology has potential across a broad array of genetic diseases. To fully realize this potential, we have established and will continue to seek out innovative collaborations, licenses,
and strategic alliances with pioneering companies and with leading academic and research institutions. Additionally, we have and will continue to pursue relationships that potentially allow us to accelerate our preclinical research and development
efforts. These relationships will allow us to aggressively pursue our vision of maximizing the potential of base editing to provide life-long cures for patients suffering from serious diseases. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Ex vivo electroporation for hematologic diseases and oncology </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Boston Children&#146;s Hospital </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July 2020, we formed a strategic alliance with Boston
Children&#146;s Hospital. Under the terms of the agreement, we will sponsor research programs at Boston Children&#146;s to facilitate development of disease-specific therapies using our proprietary base editing technology. Boston Children&#146;s
will also serve as a clinical site to advance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">bench-to-bedside</FONT></FONT> translation of our pipeline across certain therapeutic areas of interest, including programs in sickle
cell disease and pediatric leukemias and exploration of new programs targeting other diseases. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Magenta Therapeutics </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In June 2020, we announced a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> research and clinical collaboration agreement with Magenta Therapeutics to
evaluate the potential utility of <FONT STYLE="white-space:nowrap">MGTA-117,</FONT> Magenta&#146;s novel targeted ADC for conditioning of patients with sickle cell disease and beta-thalassemia receiving our base editing therapies. Conditioning is a
critical component necessary to prepare a patient&#146;s body to receive the edited cells, which carry the corrected gene and must engraft in the patient&#146;s bone marrow in order to be effective. Today&#146;s conditioning regimens rely
</FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
on nonspecific chemotherapy or radiation, which are associated with significant toxicities. <FONT STYLE="white-space:nowrap">MGTA-117</FONT> precisely targets only hematopoietic stem and
progenitor cells, sparing immune cells, and has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in <FONT STYLE="white-space:nowrap">non-human</FONT> primate models. <FONT STYLE="white-space:nowrap">MGTA-117</FONT>
may be capable of clearing space in bone marrow to support long-term engraftment and rapid recovery in patients. Combining the precision of our base editing technology with the more targeted conditioning regimen enabled by <FONT
STYLE="white-space:nowrap">MGTA-117</FONT> could further improve therapeutic outcomes for patients suffering from these severe diseases. We will be responsible for clinical trial costs related to development of our base editors when combined with <FONT
STYLE="white-space:nowrap">MGTA-117,</FONT> while Magenta will continue to be responsible for all other development costs of <FONT STYLE="white-space:nowrap">MGTA-117.</FONT> </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B><FONT STYLE="white-space:nowrap">Non-Viral</FONT> delivery for liver diseases </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Verve Therapeutics
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2019, we entered into a collaboration and license agreement with Verve Therapeutics, or Verve, a company focused on developing genetic
medicines to safely edit the genome of adults to permanently lower LDL cholesterol and triglyceride levels and thereby treat coronary heart disease. This collaboration allows us to fully realize the potential of base editing in treating
cardiovascular diseases, an area outside of our core focus where the Verve team has significant, world-class expertise. Under the terms of the agreement, Verve received exclusive access to our base editing technology, gene editing, and delivery
technologies for human therapeutic applications against certain cardiovascular targets. In exchange, we received 2,556,322 shares of Verve common stock. Additionally, we will receive milestone payments for certain clinical and regulatory events and
we retain the option, after the completion of Phase 1 studies, to participate in future development and commercialization, and share 50&nbsp;percent of U.S. profits and losses, for any product directed against these targets. Verve granted to us a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license under <FONT STYLE="white-space:nowrap">know-how</FONT> and patents controlled by Verve, and an interest in joint collaboration technology. Either party may owe the other party other milestone
payments for certain clinical and regulatory events related to the delivery technology products. Royalty payments may become due by either party to the other based on the net sales of any commercialized delivery technology products under the
agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In June 2020, Verve reported preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT>
data in <FONT STYLE="white-space:nowrap">non-human</FONT> primates that demonstrated the successful use of adenine base editors to turn off a gene in the liver. Utilizing ABE technology licensed from us and an optimized guide RNA packaged in an
engineered lipid nanoparticle, Verve evaluated <I>in vivo</I> liver base editing to turn off proprotein convertase subtilisin/kexin type 9 (PCSK9), a gene whose protein product elevates blood LDL cholesterol or angiopoietin-like protein 3 (ANGPTL3),
a gene whose protein product elevates blood triglyceride-rich lipoproteins. We believe these <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data, which show we can safely edit the primate genome,
represent the first successful application of the base editing technology in <FONT STYLE="white-space:nowrap">non-human</FONT> primates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In two separate
studies, seven animals were treated with the drug product targeting the PCSK9 gene and seven additional animals with the drug product targeting the ANGPTL3 gene. Whole liver editing, blood protein and lipid levels were measured at two weeks and
compared to baseline. The program targeting PCSK9 showed an average of 67% whole liver PCSK9 editing, which translated into an 89% reduction in plasma PCSK9 protein and resulted in a 59% reduction in blood LDL cholesterol levels. The program
targeting ANGPTL3 showed an average of 60% whole liver ANGPTL3 editing, which translated into a 95% reduction in plasma ANGPTL3 protein and resulted in a 64% reduction in blood triglyceride levels and 19% reduction in LDL cholesterol levels. In
addition, in studies in primary human hepatocytes, clear evidence of <FONT STYLE="white-space:nowrap">on-target</FONT> editing was observed with no evidence of <FONT STYLE="white-space:nowrap">off-target</FONT> editing. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">8 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Per the terms of our agreement with Verve, we can exercise our right to participate in the future development and
commercialization of any programs at the completion of Phase I studies. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Viral delivery for ophthalmology and CNS diseases </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>IOB </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July 2020, we announced a research
collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB). Founded in 2018 by a consortium that includes Novartis, the University Hospital of Basel and the University of Basel, IOB is a leader in basic and translational
research aimed at treating impaired vision and blindness. Clinical scientists at IOB have also helped to develop better ways to measure how vision is impacted by Stargardt disease. Additionally, researchers at IOB have developed living models of the
retina, known as organoids, which can be used to test novel therapies. Under the terms of the agreement, the companies will leverage IOB&#146;s unique expertise in the field of ophthalmology along with our novel base editing technology to advance
programs directed to the treatment of certain ocular diseases, including Stargardt disease. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Manufacturing </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To realize the full potential of base editors as a new class of medicines and to enable our parallel investment strategy in multiple delivery modalities, we are
building customized and integrated capabilities across discovery, manufacturing, and preclinical and clinical development. Due to the critical importance of high-quality manufacturing and control of production timing and <FONT
STYLE="white-space:nowrap">know-how,</FONT> we have taken steps toward establishing our own manufacturing facility, which will provide us the flexibility to manufacture numerous different drug product modalities. We believe this investment will
maximize the value of our portfolio and capabilities, the probability of technical success of our programs, and the speed at which we can provide life-long cures to patients. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In August 2020, we entered into a lease agreement with Alexandria Real Estate Equities, Inc. to build a 100,000 square foot current Good Manufacturing Practice, or cGMP, compliant manufacturing facility in Research
Triangle Park, North Carolina intended to support a broad range of clinical programs. We will invest up to $83&nbsp;million over a five-year period and anticipate that the facility will be operational by the first quarter of 2023. The project will
be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the North Carolina Economic Investment Committee, which authorizes potential reimbursements based on new tax revenues generated through the project. The facility will
be designed to support manufacturing for our <I>ex vivo</I> cell therapy programs in hematology and oncology and <I>in vivo</I> <FONT STYLE="white-space:nowrap">non-viral</FONT> delivery programs for liver diseases, with flexibility to support
manufacturing of our viral delivery programs, and ultimately, <FONT STYLE="white-space:nowrap">scale-up</FONT> to support potential commercial supply. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For our initial waves of clinical programs, we will use contract manufacturing organizations, or CMOs, with relevant manufacturing experience in genetic medicines.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our strategy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our mission is to become the
leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients
suffering from serious diseases. Key components of our strategy are as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Build a highly innovative, fully integrated genetic medicines company </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">9 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Advance &#147;waves&#148; of programs into clinical development through a highly efficient discovery and development engine </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Access the broadest range of therapeutic areas by leveraging clinically validated delivery modalities </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Reinforce our leadership position in base editing through strategic investment in our platform and new technologies </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Further expand patient access to our medicines through innovative strategic partnerships with both established and emerging companies
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Maintain a culture of innovation that captures the best of academic science and translational medicine </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of August&nbsp;31, 2020, we have attracted a talented group of industry experts and scientists as part of a highly innovative organization of 158 employees. We
have developed and consolidated significant technology and intellectual property covering the elements of base editing, as well as additional gene editing technologies and delivery modalities, with exclusive licenses from Harvard University, Broad
Institute of MIT and Harvard, Editas Medicine Inc., and Bio Palette Co., Ltd. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recent developments </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">With
the ongoing concern related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we have maintained and expanded our business continuity plans to address and mitigate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic on our business. In March 2020, to protect the health of our employees, and their families and communities, we restricted access to our offices to personnel who performed critical activities that must be completed <FONT
STYLE="white-space:nowrap">on-site,</FONT> limited the number of such personnel that can be present at our facilities at any one time, and requested that most of our employees work remotely. In May 2020, as certain states eased restrictions, we
established new protocols to better allow our full laboratory staff access to our facilities. These protocols included several shifts working over a seven days week protocol. We expect to continue incurring additional costs to ensure we adhere to
the guidelines instituted by the Centers for Disease Control and to provide a safe working environment to our onsite employees. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The extent to which the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our business, our corporate development objectives, results of operations and financial condition, including and the value of and market for our common stock, will depend on future
developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements, and the effectiveness
of actions taken globally to contain and treat the disease. Disruptions to the global economy, disruption of global healthcare systems, and other significant impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could have a
material adverse effect on our business, financial condition, results of operations and growth prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">While the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic did not significantly impact our business or results of operations during the six months ended June&nbsp;30, 2020, the length and extent of the pandemic, its consequences, and containment
efforts will determine the future impact on our operations and financial condition. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks associated with our business </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the
&#147;Risk factors&#148; section of this prospectus and in our Annual </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">10 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter
ended March 31, 2020 and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2020 (collectively, our &#147;Risk Factors&#148;). These risks include the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Base editing is a novel technology that is not yet clinically validated for human therapeutic use. The approaches we are taking to discover and develop novel
therapeutics are unproven and may never lead to marketable products. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and
product development programs or future commercialization efforts. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We may not be successful in our efforts to identify and develop potential product candidates. If these efforts are unsuccessful, we may never become a commercial
stage company or generate any revenues. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We are very early in our development efforts. All of our product candidates are still in preclinical development or earlier stages and it will be many years
before we or our collaborators commercialize a product candidate, if ever. If we are unable to advance our product candidates to clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience
significant delays in doing so, our business will be materially harmed. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">If any of the product candidates we may develop or the delivery modalities we rely on cause serious adverse events, undesirable side effects or unexpected
characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential, or result in significant negative consequences following any potential marketing
approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval
before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The continuing effects and impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could have a material adverse effect on our business,
financial condition, results of operations and growth prospects. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We have not tested any of our proposed delivery modes and product candidates in clinical trials and any favorable preclinical results are not predictive of
results that may be observed in clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for,
our potential products. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The gene editing field is relatively new and is evolving rapidly. We are focusing our research and development efforts on gene editing using base editing
technology, but other gene editing technologies may be discovered that provide significant advantages over base editing, which could materially harm our business. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">11 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Because base editing is novel and the regulatory landscape that will govern any product candidates we may develop is uncertain and may change, we cannot predict
the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Genetic medicines are novel, and any product candidates we develop may be complex and difficult to manufacture. We could experience delays in satisfying
regulatory authorities or production problems that result in delays in our development or commercialization programs, limit the supply of our product candidates we may develop, or otherwise harm our business. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We currently contract with third parties for the manufacture of materials for our research programs and preclinical studies and unless and until our <FONT
STYLE="white-space:nowrap">in-house</FONT> manufacturing facility becomes operational, we expect to continue to do so for clinical trials of all of our product candidates. Even if our <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing
facility becomes operational, we may contract with third parties for manufacturing of materials for clinical trials and potential commercialization of certain of our viral delivery product candidates. This reliance on third parties, and the risk
that we are not able to successfully <FONT STYLE="white-space:nowrap">build-out</FONT> our <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing facility, increases the risk that we will not have sufficient quantities of such materials,
product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Because we are developing product candidates in the field of genetics medicines, a field that includes gene therapy and gene editing, in which there is little
clinical experience, there is increased risk that the FDA, the EMA, or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">If we are unable to obtain and maintain patent protection for any product candidates we develop and for our technology, or if the scope of the patent protection
obtained is not sufficiently broad, or if we or our licensors are unable to successfully defend our or our licensors&#146; patents against third-party challenges or enforce our or our licensors&#146; patents against third parties our competitors
could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our rights to develop and commercialize technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The intellectual property landscape around genome editing technology, including base editing, is highly dynamic, and third parties may initiate legal proceedings
alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and other intellectual property may be subject to priority disputes or inventorship
disputes or we may be subject to claims that we have infringed, misappropriated or otherwise violated the intellectual property of a third party and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be
required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop, which
could have a material adverse impact on our business. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The foregoing is only a summary of some of our risks. For a more detailed
discussion of these and other risks you should consider before making an investment in our common stock, see our Risk Factors. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">12 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Implications of being an emerging growth company and smaller reporting company </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company,
we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements, exemption from the requirements to
hold <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may take advantage of these exemptions until the last day of the fiscal year following the fifth anniversary of our initial public
offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company earlier if we have more than $1.07&nbsp;billion in annual revenue, we have more than $700.0&nbsp;million in market value
of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> (and we have been a public company for at least 12 months and have filed one annual report on Form <FONT STYLE="white-space:nowrap">10-K)</FONT> or we issue more than
$1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities over a three-year period. For so long as we remain an emerging growth company, we are permitted, and intend, to rely on exemptions from certain disclosure
requirements that are applicable to other public companies that are not emerging growth companies. We may choose to take advantage of some, but not all, of the available exemptions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company
to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such extended transition period, which means that when a standard is issued or
revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either
(i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our consolidated financial statements may
not be directly comparable to those of other public companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our
stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue is less than $100&nbsp;million during
the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250&nbsp;million or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth
companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our corporate information
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We were incorporated in Delaware in January 2017. Our principal executive offices are located at 26 Landsdowne Street, 2nd Floor, Cambridge, MA
02139, and our telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-327-8775.</FONT></FONT> Our website is www.beamtx.com. Information contained on, or that can be accessed through, our website is not part of
this prospectus. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">13 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>The offering </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Common stock offered by us </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">5,000,000 shares. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Common stock to be outstanding after this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">56,525,807 shares (57,275,807 shares if the underwriters exercise their option to purchase additional shares in full). </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Underwriters&#146; option to purchase additional shares of common stock from us </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2"><B></B>We have granted the underwriters an option to purchase up to an aggregate of additional shares of common stock from us at the public offering price, less the underwriting discounts and commissions,
for a period of 30 days after the date of this prospectus. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Use of proceeds </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We estimate that our net proceeds from the sale of our common stock in this offering will be approximately $109.8 million, after deducting underwriting discounts and commissions and estimated offering
expenses payable by us. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We intend to use the net proceeds from this offering for continued advancement of our platform technology, for continued research and development of our current portfolio of base
editing programs and for other potential programs, for conducting preclinical studies, including potential preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> of our three delivery modalities,
for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and the potential initiation of clinical studies for certain of our current programs, for <FONT STYLE="white-space:nowrap">building-out</FONT> our
<FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing facility, and for general corporate purposes. See &#147;Use of proceeds.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Dividend policy </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We do not anticipate declaring or paying any cash dividends on our capital stock in the foreseeable future. See &#147;Dividend policy.&#148; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Risk factors </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">You should carefully read the &#147;Risk factors&#148; section of this prospectus and the other information included in this prospectus for a discussion of factors that you should consider before deciding
to invest in our common stock. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Nasdaq Global Select Market symbol </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">BEAM </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The number of shares of common stock to be outstanding following this offering is based
on 51,525,807 shares of common stock outstanding as of June&nbsp;30, 2020, which includes 1,880,070 shares of unvested restricted stock, which are not included as outstanding for accounting purposes and are not included as outstanding shares in our
consolidated financial statements, and excludes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5,646,046 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2020 under our 2019 Equity Incentive Plan, or the
2019 Plan, at a weighted average exercise price of $7.44 per share; </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">14 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2,605,173 shares of common stock reserved for issuance under our 2019 Plan; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">465,000 shares of common stock reserved for issuance under our 2019 Employee Stock Purchase Plan, or the 2019 ESPP. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless otherwise noted, the information in this prospectus assumes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no exercise of the outstanding stock options described above; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no exercise by the underwriters of their option to purchase 750,000 additional shares. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">15 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Summary consolidated financial data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following tables set forth, for the periods and as of the dates indicated, our summary historical financial data. The statements of operations data for the years ended December&nbsp;31, 2018 and 2019 have been
derived from our audited financial statements incorporated by reference in this prospectus. The statements of operations data for the six months ended June&nbsp;30, 2019 and 2020 and the balance sheet data as of June&nbsp;30, 2020 have been derived
from our unaudited financial statements incorporated by reference in this prospectus. The unaudited financial statements have been prepared on a basis consistent with our audited financial statements and, in our opinion, contain all adjustments,
consisting only of normal and recurring adjustments, necessary for a fair presentation of such financial data. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our historical results are not
necessarily indicative of future operating results, and our operating results for the six months ended June&nbsp;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31, 2020 or any other
periods or any future year or period. You should read the information set forth below in conjunction with &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and our financial statements and the
related notes thereto appearing in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended
March&nbsp;31, 2002 and June&nbsp;30, 2020, each of which is incorporated by reference in this prospectus. For more details on how you can obtain the documents incorporated by reference in this prospectus, see &#147;Where you can find more
information&#148; and &#147;Incorporation of certain information by reference&#148; appearing elsewhere in this prospectus. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six months&nbsp;ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended<BR>December&nbsp;31,<BR>2019</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended<BR>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2020</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2019</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Consolidated Statement of Operations and&nbsp;Other Comprehensive Loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">License revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21,859</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">75,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45,741</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(54,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(30,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(75,154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(45,741</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of derivative liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss on issuance of preferred stock in connection with Blink Merger(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(49,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss on issuance of preferred stock to investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of preferred stock tranche liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest and other income, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,036</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(70,997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(64,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(31,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(78,326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(116,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unrealized gain on marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> (64,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> (31,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(78,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(116,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per common share attributable to common stockholders, basic and diluted(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(14.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(40.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,077,788</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,018,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,479,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,893,978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">16 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See Note 10 to our consolidated financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 for a
description of the Blink Merger. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See Note 14 to our consolidated financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 and Note
12 to our unaudited interim statements for the period ended June&nbsp;30, 2020 for a description of the method used to calculate basic and diluted net loss per share attributable to common stockholders. <B></B> </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As&nbsp;adjusted(4)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Balance&nbsp;Sheet&nbsp;Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash, cash equivalents and marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">227,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">337,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Working capital(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">195,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">305,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">299,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">409,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">230,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">340,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We define working capital as current assets less current liabilities. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The adjusted Balance Sheet Data reflects the issuance and sale of 5,000,000 shares of our common stock in this offering. </FONT></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">17 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_2"></A>Risk factors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Investing in our common stock involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks described below, together with the other information contained in this
prospectus and incorporated by reference in this prospectus, including the risk factors incorporated by reference from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, our Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2020 and other filings we make with
the SEC. </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>We believe the risks described below and incorporated by reference herein are the risks that are material to us as of the date of this
prospectus. If any of the following risks or the risks incorporated by reference herein occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances,
the market price of our common stock could decline, and you may lose all or part of your investment. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to this offering and
ownership of our common stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>You will incur immediate and substantial dilution as a result of this offering. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If you purchase common stock in this offering, you will incur immediate and substantial dilution of $17.27 per share, representing the difference between the public
offering price of $23.50 per share, and our net tangible book value per share after giving effect to this offering. To the extent outstanding stock options are exercised, new investors may incur further dilution. For a further description of the
dilution you will experience immediately after this offering, see &#147;Dilution.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The market price of our common stock may be volatile,
which could result in substantial losses for investors purchasing shares in this offering. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If you purchase shares of common stock in this
offering you may be unable to sell those shares of common stock at or above the public offering price. The trading price of our common stock has fluctuated, and it is likely to continue to be subject to substantial fluctuations in response to
various factors, some of which are beyond our control. Since the shares were sold in our initial public offering in February 2020 at a price of $17.00 per share, the price per share of our common stock has ranged as low as $13.00 and as high as
$31.80 through September 25, 2020. Some of the factors that may cause the market price of our common stock to fluctuate include, but are not limited to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the success of existing or new competitive product candidates or technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing and results of preclinical studies for any product candidates that we may develop; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">failure or discontinuation of any of our product development and research programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs
or product candidates of our competitors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments or changing views regarding the use of genetic medicines, including those that involve gene editing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">commencement or termination of collaborations for our product development and research programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory or legal developments in the United States and other countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">18 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the recruitment or departure of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the results of our efforts to develop additional product candidates or products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">announcement or expectation of additional financing efforts; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">sales of our common stock by us, our insiders or other stockholders; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">variations in our financial results or those of companies that are perceived to be similar to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in the structure of healthcare payment systems; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">market conditions in the pharmaceutical and biotechnology sectors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">general economic, industry, and market conditions; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the other factors described or incorporated by reference in this &#147;Risk Factors&#148; section. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Additionally, the extent and duration of the impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our stock price and other biopharmaceutical companies is uncertain and may make us look less attractive to investors and, as a result, there may be a less active trading market for our common
stock and our stock price may be more volatile. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the
trading market for our stock shortly following this offering. Following periods of such volatility in the market price of a company&#146;s securities, securities class action litigation has often been brought against that company. Because of the
potential volatility of our stock price, we may become the target of securities litigation in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Securities litigation could result in
substantial costs and divert management&#146;s attention and resources from our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>A significant portion of our total outstanding shares is
restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the
holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. After this offering we will have 56,525,807 shares of common stock outstanding, or 57,275,807 shares if the underwriters
exercise their option to purchase additional shares in full, in each case based on the 51,525,807 shares of our common stock outstanding as of June&nbsp;30, 2020. Common stock outstanding includes 1,880,070 shares of unvested restricted
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">19 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
stock, which are not included as outstanding for accounting purposes and are not included as outstanding shares in our consolidated financial statements. Subject to the restrictions set forth in
the <FONT STYLE="white-space:nowrap">90-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to be entered into by each of our directors and officers in connection with this offering as described elsewhere in this prospectus under
the heading &#147;Underwriting&#148; (which restrictions may be waived, with or without notice, by J.P. Morgan Securities and Jefferies LLC), outstanding shares of our common stock may be freely sold in the public market at any time to the extent
permitted by Rules 144 and 701 under the Securities Act of 1933, as amended, or the Securities Act, or to the extent that such shares have already been registered under the Securities Act and are held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> of ours. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Moreover, after this offering, holders of an aggregate of 15,231,958 shares of our
common stock will have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also have
registered all shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to
volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the &#147;Underwriting&#148; Section of this prospectus. If any of these additional shares are sold, or if it is perceived
that they will be sold, in the public market, the market price of our common stock could decline. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Insiders will continue to have substantial
influence over us after this offering, which could limit your ability to affect the outcome of key transactions, including a change of control. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After this offering, our directors and executive officers and their affiliates will beneficially own shares representing approximately 30.5% of our outstanding
common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate
transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our management will have broad discretion in the application of the net proceeds, including for any of
the purposes described in &#147;Use of proceeds.&#148; Accordingly, you will have to rely upon the judgment of our management with respect to the use of the proceeds, with only limited information concerning management&#146;s specific intentions.
Our management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could harm our
business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our relationships with third parties </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Public health epidemics or outbreaks, including <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely impact our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Due to the evolving and uncertain global impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we cannot precisely determine or quantify the
impact this pandemic will have on our business operations for the remainder of our fiscal year ending December&nbsp;31, 2020 or beyond. The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> may impact our business, results of
operations and future growth prospects will depend on a variety of factors and future developments, which are highly uncertain and cannot be predicted with confidence, including the ultimate geographic spread of the disease, the duration, scope and
severity of the pandemic, the duration and extent of travel restrictions and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">20 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The rapid spread of the virus has led to the implementation of various responses, including
government-imposed quarantines, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> mandates, sweeping restrictions on travel, and other public health safety measures, as well as reported
adverse impacts on healthcare resources, facilities and providers, in Massachusetts, where our primary offices and laboratory spaces are located, across the United States, and in other countries. The extent to which
<FONT STYLE="white-space:nowrap">COVID-19</FONT> continues to impact our operations and those of our third-party partners will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration
of the outbreak, additional or modified government actions, new information which may emerge concerning the severity of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the actions taken to contain
<FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its impact, among others. As interventions to contain the spread of the virus are lifted or reduced, new <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreaks may result in new or
heightened restrictions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To protect the health of our employees and their families, and our communities, in accordance with direction from state and
local government authorities, we restricted access to our facilities to personnel and third parties who must perform critical activities that must be completed <FONT STYLE="white-space:nowrap">on-site,</FONT> limited the number of such personnel
that can be present at our facilities at any one time, and requested that some of our personnel work remotely. We plan to maintain these or similar restrictions until we believe employees can fully resume such activities in accordance with federal,
state and local requirements. In the event that governmental authorities were to increase current restrictions, our employees conducting research and development, or manufacturing activities may not be able to access our laboratory or manufacturing
space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has also impacted, and may continue to impact, our third-party suppliers, including through the effects of facility closures, reductions in operating hours, staggered shifts and other social
distancing efforts, labor shortages, decreased productivity and unavailability of materials or components. While we maintain an inventory of materials necessary to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, a prolonged
outbreak could lead to shortages in these materials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, timely completion of preclinical activities is dependent upon the availability of,
for example, preclinical sites, researchers and investigators, regulatory agency personnel, and materials, which may be adversely affected by global health matters, such as pandemics. We plan to conduct preclinical activities for our programs in
geographies which are currently being affected by <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some factors from the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic that could delay or otherwise adversely affect the completion of our preclinical activities and, depending on the duration of the outbreak, the initiation of any future clinical trials, as
well as our business generally, include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or
delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations, cyber security and data accessibility, or communication or mass transit disruptions, any of which could adversely impact our business operations or
delay necessary interactions with local regulators, ethics committees, manufacturing sites, research sites and other important agencies and contractors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limitations on our business operations by local, state, or the federal government that could impact our ability to conduct our preclinical activities, including
completing our <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limitations on travel that could hinder our timelines; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">interruption in global shipping affecting the transport of key materials; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">21 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">interruption of, or delays in receiving, key materials from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages
and disruptions in delivery systems. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These and other factors arising from <FONT STYLE="white-space:nowrap">COVID-19</FONT> could
worsen in countries that are already afflicted with <FONT STYLE="white-space:nowrap">COVID-19</FONT> or could continue to spread to additional countries, each of which could further adversely impact our ability to conduct preclinical or any future
clinical trials, and, in general, our business, and could have a material adverse impact on our operations and financial condition and results. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, the extent and duration of the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our stock price and other biopharmaceutical
companies is uncertain and may make us look less attractive to investors and, as a result, there may be a less active trading market for our common stock, our stock price may be more volatile, and our ability to raise capital could be impaired.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak continues to rapidly evolve. The extent to which the outbreak may impact our business,
preclinical studies and any future clinical trials will highly depend on future developments, which are very uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak,
travel restrictions and other actions to contain the outbreak or address its impact, such as social distancing and quarantines or lockdowns in the United States and other countries, business closures or business disruptions and the effectiveness of
actions taken in the United States and other countries to contain and address the disease. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
may also have the effect of heightening many of the other risks described in this section titled &#147;Item 1A. Risk Factors&#148;, such as risks related to our need to raise additional funding, fluctuation of our quarterly financial results, and
our ability to obtain and maintain regulatory approvals. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">22 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_3"></A>Special note regarding forward-looking statements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus and documents incorporated by reference herein contain forward-looking statements. All statements other than statements of historical facts
contained in this prospectus and the documents incorporated by reference herein are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148;
&#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148;
&#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements
concerning: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the initiation, timing, progress and results of our research and development programs and preclinical and clinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to demonstrate, and the timing of, preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in
vivo for multiple programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to advance any product candidates that we may develop and successfully complete any clinical studies, including the manufacture of any such product
candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to pursue a comprehensive suite of clinically validated delivery modalities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to quickly leverage our initial programs and to progress additional programs to create a clinical portfolio; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing of our &#147;waves&#148; of investigational new drug applications filings; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the implementation of our strategic plans for our business, programs, product candidates, and technology; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments related to our competitors and our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to leverage the clinical, regulatory, and manufacturing advancements made by gene therapy and gene editing programs to accelerate our clinical trials
and approval of product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to identify and enter into future license agreements and collaborations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments related to base editing technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to successfully develop our three distinct pipelines and obtain and maintain approval for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to successfully <FONT STYLE="white-space:nowrap">build-out</FONT> our <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing facility;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory developments in the United States and foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to attract and retain key scientific and management personnel; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our use of proceeds from this offering, estimates of our expenses, capital requirements, and needs for additional financing. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The forward-looking statements in this prospectus are only predictions and are based largely on our current expectations and projections about future events and
financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus or the documents incorporated by reference herein and are subject
to a number of known and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">23 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
unknown risks, uncertainties and assumptions, including those described in this prospectus and in Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year
ended December&nbsp;31, 2019, the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020, the Company&#146;s Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2020 and other filings we make with the SEC. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or
quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and
actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to
predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed
circumstances or otherwise. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">24 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_4"></A>Use of proceeds </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds to us from the sale of the shares of common stock in this offering will be approximately $109.8 million, or approximately $126.3 million if the underwriters exercise their option
to purchase additional shares in full, after deducting underwriting discounts and commissions and estimated offering expenses. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2020,
we had cash, cash equivalents, and marketable securities of $228.0&nbsp;million. We currently expect to use the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities as of June&nbsp;30, 2020
for continued advancement of our platform technology, for continued research and development of our current portfolio of base editing programs and for other potential programs, for conducting preclinical studies, including potential preclinical <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> of our three delivery modalities, for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and the potential initiation of clinical studies for
certain of our current programs, for <FONT STYLE="white-space:nowrap">building-out</FONT> our <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing facility, and for general corporate purposes. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All of our programs are currently in preclinical stage of development. The specific allocation of the proceeds from this offering and our current cash, cash
equivalents, and marketable securities towards specific programs will depend on, among other things, results from our research and development efforts for each program, the timing and success of our preclinical studies and the timing and outcome of
regulatory submissions. As a result, and due to the number of our programs currently in preclinical development, we currently are unable to specify to what stage of development the proceeds from this offering and our current cash, cash equivalents,
and marketable securities will bring any particular program. We expect the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities, will not be sufficient for us to advance any of our programs
through regulatory approval or to complete our planned manufacturing facility, and we will need to raise additional capital to complete the development and potential commercialization of any of our programs and our planned manufacturing facility.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may also use a portion of the net proceeds from this offering to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or invest in products,
technologies or businesses that are complementary to our business. The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our preclinical development efforts, our operating costs and other
factors described under &#147;Risk factors&#148; in this prospectus and the documents incorporated by reference herein. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our expected use of net proceeds
from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot predict with complete certainty all of the particular uses for the net proceeds to be received
upon the completion of this offering or the actual amounts that we will spend on the uses set forth above. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Based on our planned use of the net proceeds
from this offering and our existing cash, cash equivalents and marketable securities, we estimate that such funds will be sufficient to enable us to fund our operating expenses, debt service, and capital expenditure requirements through at least the
next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the
net proceeds from this offering in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">25 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_5"></A>Dividend policy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash
dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business
prospects and other factors our board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. Our ability to pay cash dividends on our capital stock in the future may also be limited by the terms
of any preferred securities we may issue or agreements governing any indebtedness we may incur. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">26 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_6"></A>Capitalization </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table summarizes our cash, cash equivalents, and marketable securities and capitalization as of June&nbsp;30, 2020: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an as adjusted basis, to further reflect the sale and issuance by us of 5,000,000 shares of common stock in this offering at the public offering price of
$23.50 per share, after deducting underwriting discounts and commissions and estimated offering expenses. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">You should read the
information in this table together with the consolidated financial statements and related notes to those statements, as well as the information set forth in Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
year ended December&nbsp;31, 2019, the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020, the Company&#146;s Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2020 and other filings we make with the SEC. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of June&nbsp;30, 2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except share and per share amounts)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As&nbsp;adjusted</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash, cash equivalents and marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">227,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">337,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stockholders&#146; equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Common stock ($0.01 par value; actual: 250,000,000 shares authorized, 51,525,807 shares issued, and 49,645,737 shares outstanding; as
adjusted: 250,000,000 shares authorized, 56,525,807 shares issued, and 54,645,737 shares outstanding)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">546</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">497,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">607,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(267,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(267,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">230,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">340,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">230,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">340,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The outstanding share information in the table above excludes as of June&nbsp;30, 2020: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5,646,046 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2020 under our 2019 Plan, at a weighted average
exercise price of $7.44 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2,605,173 shares of common stock reserved for issuance under our 2019 Plan; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">465,000 shares of common stock reserved for issuance under our 2019 ESPP. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">27 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_7"></A>Dilution </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If you invest in our common stock in this offering, you will experience immediate and substantial dilution in the adjusted net tangible book value of your shares of common stock. Dilution in adjusted net tangible
book value represents the difference between the initial price to the public per share of our common stock and the adjusted net tangible book value per share of our common stock immediately after this offering. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net tangible book value per share represents our total tangible assets, including operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets of $22.9&nbsp;million, less total liabilities divided by the number of shares of outstanding common stock as of June&nbsp;30, 2020, or 49,645,737
shares. The historical net tangible book value of our common stock as of June&nbsp;30, 2020 was $230.8&nbsp;million, or $4.65 per share. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After giving
effect to our sale of 5,000,000 shares of common stock in this offering at the public offering price $23.50 per share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our adjusted net
tangible book value as of June&nbsp;30, 2020 would have been approximately $340.6&nbsp;million, or $6.23 per share. This represents an immediate increase in adjusted net tangible book value of $1.58 per share to existing stockholders and an
immediate dilution of $17.27 per share to investors participating in this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table illustrates this dilution on a per share basis
to new investors: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Public offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Historical net tangible book value per share of common stock as of June&nbsp;30, 2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Increase in net tangible book value per share of common stock attributable to this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjusted net tangible book value per share of common stock after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Dilution per share of common stock to new investors participating in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the underwriters exercise in full their option to purchase additional shares of common stock from us in this offering, our
adjusted net tangible book value per share after the offering would be $6.45, and the dilution per share to new investors would be $17.05, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes, on the as adjusted basis as of June&nbsp;30, 2020, the differences between the number of shares of common stock
purchased from us, the total consideration paid to us in cash and the average price per share paid by existing stockholders and by investors participating in this offering. The table below excludes 5,314,658 shares, as of June&nbsp;30, 2020, for
which no cash consideration was received. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares purchased</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total consideration</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Average&nbsp;price<BR>per share</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Common and preferred</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Existing stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44,331,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">89.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">431,280,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">78.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">New investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">117,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49,331,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">548,780,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, if the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares held by
existing stockholders will be reduced to 88.5% of the total number of shares of common stock to be outstanding upon completion of this offering, and the number of shares of common stock held by investors participating in this offering will be
further increased to 11.5% of the total number of shares of common stock to be outstanding upon completion of the offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">28 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The outstanding share information in the tables above excludes: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5,646,046 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2020 under our 2019 Plan, at a weighted average
exercise price of $7.44 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2,605,173 shares of common stock reserved for issuance under our 2019 Plan; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">465,000 shares of common stock reserved for issuance under our 2019 ESPP. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Furthermore, we may choose to raise additional capital through the sale of equity or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for
our current or future operating plans. New investors will experience further dilution if any of our outstanding options are exercised, new options are issued and exercised under our equity incentive plans or we issue additional shares of common
stock, other equity securities or convertible debt securities for lower consideration per share than in this offering in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">29 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_8"></A>Market price of our common stock </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;BEAM.&#148; On September&nbsp;25, 2020, the closing price for our common stock
as reported on the Nasdaq Global Select Market was $26.76 per share. As of August&nbsp;31, 2020, we had 69 holders of record of our common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">30 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_9"></A>Principal stockholders </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table sets forth certain information with respect to the beneficial ownership of our common stock at August&nbsp;31, 2020, as adjusted to reflect the sale of common stock offered by us in this
offering, for: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each person who we know beneficially owns more than 5% of our common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each of our directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each of our named executive officers; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">all of our directors and executive officers as a group. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, a person is deemed to be a &#147;beneficial&#148; owner of a security if that person has
or shares voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. Except as indicated in the footnotes below, we believe, based on the information furnished to us, that the individuals
and entities named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned by them, subject to any applicable community property laws. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">31 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Percentage ownership of our common stock before this offering is based on 51,764,067 shares of our common stock
outstanding as of August&nbsp;31, 2020. Outstanding common stock as of August&nbsp;31, 2020 includes 1,621,497 shares of unvested restricted stock, which are not included as outstanding for accounting purposes and are not included as outstanding
shares in our consolidated financial statements. Percentage ownership of our common stock after this offering is based on 56,764,067 shares of our common stock outstanding as of August&nbsp;31, 2020, after giving effect to the issuance of 5,000,000
shares of our common stock in this offering. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options, warrants or other rights held by
such person that are currently exercisable or that will become exercisable within 60 days of August&nbsp;31, 2020 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of
any other person. Unless noted otherwise, the address of all listed stockholders is 26 Landsdowne Street, 2nd Floor, Cambridge, MA 02139. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number of<BR>shares<BR>beneficially<BR>owned</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage&nbsp;of&nbsp;shares<BR>beneficially owned</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name of beneficial owner</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Before<BR>offering</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>After<BR>offering</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>5% or greater stockholders:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Funds affiliated with ARCH Venture Partners(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,243,039</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund V LP(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,971,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David Liu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,258,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">HH Beam Holdings LLC(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,671,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Feng Zhang</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,588,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Directors and Named Executive Officers:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">John Evans(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,505,712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Giuseppe Ciaramella(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">304,877</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Terry-Ann</FONT> Burrell (6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">113,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Kristina Burow</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Graham Cooper</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Mark Fishman, M.D.(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">163,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stephen Knight, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Carole Ho, M.D.(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Robert Nelsen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">All executive officers and directors as a group (9 persons)(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,120,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Less than 1% </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents (a) 4,121,519 shares of common stock held by ARCH Venture Fund IX Overage, L.P., or ARCH IX Overage, and (b) 4,121,520 shares of common stock held by ARCH Venture Fund
IX, L.P., or ARCH IX. ARCH Venture Partners IX Overage, L.P., or the GPLP, as the sole general partner of ARCH IX Overage, has the power to vote and dispose of the shares held of record by ARCH IX Overage and may be deemed to beneficially own
certain of the shares held of record by ARCH IX Overage. ARCH Venture Partners IX, L.P., or AVP IX LP, has the power top vote and dispose of the shares held of record by ARCH IX and may be deemed to beneficially own certain of the shares held of
record by ARCH IX. GPLP and AVP IX LP disclaim beneficial ownership of all shares held of record by ARCH IX Overage and ARCH IX, respectively, in which the GPLP or AVP IX LP does not have an actual pecuniary interest. ARCH Venture Partners IX, LLC,
or the GPLLC, as the sole general partner of the GPLP and AVP IX LP, has the power to vote and dispose of the shares held of record by ARCH IX Overage and ARCH IX and may be deemed to beneficially own certain of the shares held of record by ARCH IX
Overage and ARCH IX. The GPLLC disclaims beneficial ownership of all shares held of record by ARCH IX Overage and ARCH IX in which it does not have an actual pecuniary interest. Keith Crandell, Clinton Bybee, and Robert Nelsen are the managing
directors of the GPLLC, share the power to vote and dispose of the shares held of record by ARCH IX Overage and ARCH IX and may be deemed to beneficially own certain of the shares held of record by ARCH IX Overage and ARCH IX. The managing directors
disclaim beneficial ownership of all shares held of record by ARCH IX Overage and ARCH IX in which they do not have an actual pecuniary interest. The address of all filing persons is 8755 W. Higgins Road, Suite 1025, Chicago, IL 60631.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Consists of 6,971,912 shares held by <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund V LP.
<FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Advisors Fund V LP is the general partner of <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund V LP.
<FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Advisors Fund V LP is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">32 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="1">
owned, directly or indirectly, by various shareholders and employees of FMR LLC. Each of the entities listed above expressly disclaims beneficial ownership of the securities listed above except
to the extent of any pecuniary interest therein. The address of these entities is 245 Summer Street, Boston, MA 02210. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of 2,671,403 shares held by HH Beam Holdings LLC. HH Beam Holdings LLC is beneficially owned and controlled by Hillhouse Fund IV, L.P. Hillhouse Capital Management, Ltd.
acts as the sole management company of Hillhouse Fund IV, L.P., which is in turn ultimately controlled by Mr.&nbsp;Lei Zhang. The registered address of HH Beam Holdings LLC is Citco Trustees (Cayman) Limited, 89 Nexus Way, Camana Bay, PO Box 31106,
Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1205,</FONT> Cayman Islands. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes 351,817 shares of unvested restricted stock as of August&nbsp;31, 2020 that Mr.&nbsp;Evans has the ability to vote. Includes options to purchase 289,455 shares of common
stock that are exercisable within 60 days of August&nbsp;31, 2020. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes options to purchase 304,877 shares of common stock that are exercisable within 60 days of August&nbsp;31, 2020. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes options to purchase 113,822 shares of common stock that are exercisable within 60 days of August&nbsp;31, 2020. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes options to purchase 146,383 shares of common stock that are exercisable within 60 days of August&nbsp;31, 2020. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes options to purchase 32,334 shares of common stock that are exercisable within 60 days of August&nbsp;31, 2020. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes 351,817 shares of unvested restricted stock as of June&nbsp;30, 2020 that Mr.&nbsp;Evans has the ability to vote. Includes options to purchase 886,871 shares of common
stock that are exercisable within 60 days of August&nbsp;31, 2020. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">33 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_10"></A>Description of capital stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>General </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our authorized capital stock consists of 275,000,000 shares, all with a par value of $0.01 per share,
of which: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">250,000,000 shares are designated as common stock; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">25,000,000 shares are designated as preferred stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Common stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Holders of our common stock are entitled to one vote for each share held on all matters submitted
to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are
entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to
stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares
of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock
that we may designate and issue in the future. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Preferred stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our
board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred
stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays
associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more
difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Anti-takeover effects of our certificate of incorporation and our <FONT STYLE="white-space:nowrap">by-laws</FONT> </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> contains certain provisions that are intended to enhance the likelihood of
continuity and stability in the composition of our board of directors but which may have the effect of delaying, deferring or preventing a future takeover or change in control of us unless such takeover or change in control is approved by our board
of directors. These provisions include: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Classified board.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that our board of
directors will be divided into three classes of directors, with the classes as nearly equal in number as possible. As a result, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of our board of directors are elected each year. The
classification of directors will have the effect of making it </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">34 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
more difficult for stockholders to change the composition of our board. Our certificate of incorporation also provides that, subject to any rights of holders of preferred stock to elect
additional directors under specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by our board of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Action by written consent; special meetings of stockholders.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that stockholder action can be taken only at an annual or special meeting of
stockholders and cannot be taken by written consent in lieu of a meeting. Our certificate of incorporation and the <FONT STYLE="white-space:nowrap">by-laws</FONT> also provides that, except as otherwise required by law, special meetings of the
stockholders can only be called pursuant to a resolution adopted by a majority of our board of directors. Except as described above, stockholders are not permitted to call a special meeting or to require our board of directors to call a special
meeting. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Removal of directors.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that our directors may be removed only for cause
by the affirmative vote of at least 75% of the voting power of our outstanding shares of capital stock, voting together as a single class. This requirement of a supermajority vote to remove directors could enable a minority of our stockholders to
prevent a change in the composition of our board. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Advance notice procedures.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our
<FONT STYLE="white-space:nowrap">by-laws</FONT> establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of
directors. Stockholders at an annual meeting are only able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder who was a
stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder&#146;s intention to bring that business before the meeting.
Although the <FONT STYLE="white-space:nowrap">by-laws</FONT> do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual
meeting, the <FONT STYLE="white-space:nowrap">by-laws</FONT> may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a
solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Supermajority approval
requirements.</I>&nbsp;&nbsp;&nbsp;&nbsp;The DGCL generally provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or <FONT
STYLE="white-space:nowrap">by-laws,</FONT> unless either a corporation&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> requires a greater percentage. Our certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws</FONT> provide that the affirmative vote of holders of at least 75% of the total votes eligible to be cast in the election of directors is required to amend, alter, change or repeal specified provisions. This
requirement of a supermajority vote to approve amendments to our certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> could enable a minority of our stockholders to exercise veto power over any such amendments.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Authorized but unissued shares.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our authorized but unissued shares of common stock and preferred stock are available for
future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The
existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Exclusive forum.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation requires, to the fullest extent permitted by law, that derivative
actions brought in the name of the Company, actions against directors, officers and employees for breach of a fiduciary duty and other similar actions may be brought only in specified courts in the State of Delaware. Under our certificate of
incorporation, this exclusive forum provision will not apply to claims that are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">35 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction and explicitly does not apply to actions arising under federal securities laws,
including suits brought to enforce any liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Furthermore, our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> also provide that
unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any compliant asserting a cause of action arising under the Securities Act.
Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, these provisions may have the effect of discouraging lawsuits against our directors
and officers. See &#147;Risk <FONT STYLE="white-space:nowrap">factors-Our</FONT> amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> designate the state or federal courts within
the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our
directors, officers or employees.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Section&nbsp;203 of the DGCL </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an
&#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes,
among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or did own
within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#146;s voting stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under
Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: before the stockholder became interested, our board of directors approved either the
business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee
stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by our board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the
affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or <FONT
STYLE="white-space:nowrap">by-laws</FONT> resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in
control attempts of us may be discouraged or prevented. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Transfer agent and registrar </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Listing
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;BEAM.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">36 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_11"></A>Material U.S. federal income tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our common stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following discussion is a summary of the material U.S. federal
income tax consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of
all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the
U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case, in
effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This discussion is
limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not
address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment income or the alternative
minimum tax. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">U.S. expatriates and former citizens or long-term residents of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated
investment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">banks, insurance companies and other financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">brokers, dealers or traders in securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that accumulate earnings to avoid U.S. federal
income tax; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons deemed to sell our common stock under the constructive sale provisions of the Code; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which are held by qualified
foreign pension funds; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock being taken into account in an
applicable financial statement. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">37 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This discussion does not address the tax treatment of partnerships or other pass-through entities, or persons who hold
our common stock through partnerships or other pass-through entities, for U.S. federal income tax purposes. If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a
partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships
should consult their tax advisors regarding the U.S. federal income tax consequences to them. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND
IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS, AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR
COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Definition of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor an entity or
arrangement treated as a partnership for U.S. federal income tax purposes (or a partner thereof). A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning
of Section&nbsp;7701(a)(30) of the Code) or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Distributions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As described in the section entitled &#147;Dividend policy,&#148; we do not anticipate declaring
or paying any distributions to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to
the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be
applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under
&#147;&#151;Sale or other taxable disposition of our common stock.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the discussion below on effectively connected income, FATCA, and
backup withholding, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by
an applicable income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) certifying qualification for the lower treaty rate. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not
timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">38 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent
establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or successor form), certifying that the dividends are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any such effectively connected
dividends will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such
lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits attributable to such dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their
tax advisors regarding any applicable tax treaties that may provide for different rules. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Sale or other taxable disposition of our common stock
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the discussion below on backup withholding and FATCA, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to
U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States
(and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is attributable); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States for 183 days or more during the
taxable year of the disposition and certain other requirements are met; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property holding corporation, or USRPHC, for U.S.
federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a
net income basis at the regular graduated rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax
treaty) on its effectively connected earnings and profits attributable to such gain, as adjusted for certain items. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Gain described in the second bullet
point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.-source capital losses (even though the individual is not considered a
resident of the United States), provided that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">With respect to the third bullet point above, we believe we currently are not, and we do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends on the fair market value of
our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there can be no assurance we are not currently a USRPHC or will not become a USRPHC in the
future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax if our common
stock is &#147;regularly traded&#148; (as defined by applicable Treasury Regulations) on an established securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common
stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for
different rules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">39 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Information reporting and backup withholding </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Payments of dividends on our common stock will not be subject to backup withholding, provided the holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status by furnishing a valid IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or successor forms) or otherwise establishes an exemption. However,
information returns are required to be filed with the IRS in connection with any dividends on our common stock paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition,
proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable
withholding agent receives the certification described above or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Copies of information
returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is
established. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Additional withholding tax on payments made to foreign accounts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Withholding taxes may be imposed under
Sections 1471 to 1474 of the Code and related Treasury Regulations and guidance, or FATCA, on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on our common stock paid to a &#147;foreign financial institution&#148; or a
<FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the
diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States
persons&#148; or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT>
foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on our common stock. While
withholding under FATCA would have also applied to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019, recently proposed Treasury Regulations eliminate FATCA withholding on payments of gross
proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prospective
investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">40 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_12"></A>Underwriting </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, Jefferies LLC and Barclays Capital Inc. are acting as joint <FONT
STYLE="white-space:nowrap">book-running</FONT> managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting
agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of
shares of common stock listed next to its name in the following table: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">J.P. Morgan Securities LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Jefferies LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,575,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Barclays Capital Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">800,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Wedbush Securities Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters are committed to purchase all the common shares offered by us if they purchase any shares. The underwriting
agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters propose to offer the common shares directly to the public at the public offering price set forth on the cover page of this prospectus and to
certain dealers at that price less a concession not in excess of $0.846 per share. After the offering of the shares to the public, if all of the shares of common stock are not sold at the public offering price, the underwriters may change the
offering price and the other selling terms. Sales of shares made outside of the United States may be made by affiliates of the underwriters. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
underwriters have an option to buy up to 750,000 additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date
of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table
above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $1.41 per share. The following
table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Without<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>With full<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Per Share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,050,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,107,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and
accounting expenses, but excluding the underwriting discounts and commissions, will be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">41 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
approximately $700,000. We have also agreed to reimburse the underwriters for certain of their expenses in an amount of up to $40,000. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to
allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make
Internet distributions on the same basis as other allocations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We<I> </I>have agreed that we will not (i)&nbsp;offer, pledge, announce the intention to
sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or file with the Securities and Exchange
Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make any
offer, sale, pledge, disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities
(regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Jefferies
LLC, for a period of 90 days after the date of this prospectus, other than (A)&nbsp;the shares of our common stock to be sold hereunder, (B)&nbsp;any shares of our common stock issued upon the exercise of options granted under our existing stock
compensation plans, or Company Share Plans, (C)&nbsp;any options and other awards granted under a Company Share Plan, (D)&nbsp;the filing by us of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form
thereto relating to a Company Share Plan, and (E)&nbsp;shares of our common stock or other securities issued in connection with a transaction with an unaffiliated third party that includes a bona fide commercial relationship (including joint
ventures, marketing or distribution arrangements, collaboration agreements or licensing agreements) or any acquisition of assets of not less than a majority or controlling portion of the equity of another entity, provided that (x)&nbsp;the aggregate
number of the shares issued pursuant to clause (E)&nbsp;shall not exceed more than ten percent (10%) of the total number of outstanding shares of our common stock immediately following this offering, and (y)&nbsp;the recipient of any such shares of
our common stock or securities issued pursuant to clauses (B), (C), and (E)&nbsp;during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period shall enter into (if it has not previously entered into) a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our directors and executive officers, and certain of our significant shareholders have
entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each of these persons or entities, with limited exceptions, for a period of 90&nbsp;days after
the date of this prospectus, may not, without the prior written consent of J.P. Morgan Securities LLC and Jefferies LLC, and will not cause any direct or indirect affiliate to, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or
exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such directors, executive officers, managers and members in accordance with the
rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or (2)&nbsp;enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic
consequences of ownership of the common stock or such other securities, whether any such transaction described in clause&nbsp;(1) or&nbsp;(2) above is to be settled by delivery of common stock or such other securities, in cash or otherwise,
(3)&nbsp;make any demand for or exercise any right with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock, or (4)&nbsp;publicly disclose the intention
to do any of the foregoing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">42 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notwithstanding the foregoing, the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements generally
do not apply to or prohibit, among others, the items described below: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(A) transfers of shares of common stock or any security convertible into or
exercisable or exchangeable for common stock as a bona fide gift or gifts or for bona fide estate planning purposes, including without limitation transfers to charitable organizations, </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">(B) transfers or distributions of shares of common stock or any security convertible into or exercisable or exchangeable for common stock to (a)&nbsp;limited partners, members, stockholders or holders of similar
equity interests or (b)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party, including without limitation any general partner, limited partner, managing member, manager, member, employee, officer or director of such entity or any trust for the benefit of any of the foregoing
or any affiliate of the foregoing, or to any investment fund or other entity controlled or managed by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or affiliates of such party, </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">(C) transactions relating to common stock acquired in this offering or open market transactions after the completion of this offering, </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">(D) transfers or dispositions of common stock or any security convertible into or exercisable or exchangeable for common stock by will or intestacy, provided that any required filing under the Exchange Act, shall
clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause and no other public filing, report or announcement shall be required or made voluntarily in connection with such transfer or disposition
or (ii)&nbsp;to any family member or to a trust whose beneficiaries consist exclusively of one or more of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and/or a family member, </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">(E) transfers of common stock or any security convertible into or exercisable or exchangeable for common stock pursuant to a domestic order or negotiated divorce settlement, provided that any required filing under
the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause and no other public filing, report or announcement shall be required or made voluntarily in connection with such
transfer or disposition, </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(F) the exercise of a warrant or the exercise of a stock option granted under a stock incentive plan described in this
prospectus, provided that the underlying common stock received shall continue to be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions, and provided further that no filing under the Exchange Act or other public filing,
report or announcement shall be voluntarily made during the period beginning on the date hereof and continuing to and including the date that is 30 days after the date of this prospectus, or the <FONT STYLE="white-space:nowrap">30-Day</FONT> Period,
and after the <FONT STYLE="white-space:nowrap">30-Day</FONT> Period no public filing, report or announcement is voluntarily made, and if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is required to make any public filing, report or
announcement under the Exchange Act, such public filing, report or announcement shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause, that no common stock was sold by the reporting
person and that common stock so received is subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions, </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(G)&nbsp;&nbsp;&nbsp;&nbsp;transfers or dispositions of restricted stock to the company pursuant to any contractual arrangement in effect on the date of this
offering and described in this prospectus that provides for the repurchase of the common stock in connection with the termination of services to the company, provided that no filing under the Exchange Act or other public filing, report or
announcement shall be voluntarily made during the <FONT STYLE="white-space:nowrap">30-Day</FONT> Period, and after the <FONT STYLE="white-space:nowrap">30-Day</FONT> Period no public filing, report or announcement is voluntarily made, and if the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party is required to make any public filing, report or announcement under the Exchange Act, such public filing, report or announcement shall clearly indicate in the footnotes thereto that the filing relates
to the circumstances described in this clause, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">43 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(H)&nbsp;&nbsp;&nbsp;&nbsp;the disposition of common stock to the company, or the withholding of common stock by the
company, in a transaction exempt from the Exchange Act solely in connection with the payment of taxes due with respect to the vesting of restricted stock granted under a stock incentive plan or pursuant to a contractual employment arrangement
described in this prospectus, insofar as such restricted stock is outstanding as of the date of this prospectus, provided that no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made during the <FONT
STYLE="white-space:nowrap">30-Day</FONT> Period, and after the <FONT STYLE="white-space:nowrap">30-Day</FONT> Period no public filing, report or announcement is voluntarily made, and if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is
required to make any public filing, report or announcement under Section&nbsp;16 of the Exchange Act, such public filing, report or announcement shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described
in this clause, </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(I) the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the
transfer of common stock, provided that (a)&nbsp;such plan does not provide for the transfer of common stock during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period and (b)&nbsp;the entry into such plan is not publicly disclosed, included
in any filings under the Exchange Act or otherwise, during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, and </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(J)&nbsp;&nbsp;&nbsp;&nbsp;pursuant to a bona fide third party tender offer for all outstanding common stock of the company, merger, consolidation or other similar
transaction approved by the company&#146;s Board of Directors and made to all holders of the company&#146;s securities involving a change of control of the company (including, without limitation, the entering into of any <FONT
STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party may agree to transfer, sell, tender or otherwise dispose of Common Stock or other such securities in
connection with such transaction, or vote any Common Stock or other such securities in favor of any such transaction), provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such
securities shall remain subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><U>provided</U> that in the case of any transfer or
distribution pursuant to clause (A), (B), (D) or (E), each donee or distributee shall be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions; and provided, further, that in the case of any transfer or distribution pursuant to
clause (A), (B), (C) or (D)(ii), no filing by any party (donor, donee, transferor or transferee) under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution
(other than a filing on a Form 5 made after the expiration of the <FONT STYLE="white-space:nowrap">30-Day</FONT> Period); and provided, further, in the case of clauses (B)&nbsp;and (D)(ii), any such transfer shall not involve a disposition for
value. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;BEAM.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of
preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common stock, which involves the sale by the underwriters of a greater
number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short
positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that amount. The underwriters may close out any covered
short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares
available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">44 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the
underwriters create a naked short position, they will purchase shares in the open market to cover the position. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters have advised us that,
pursuant to Regulation&nbsp;M of the Securities Act of 1933, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the
representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the
underwriting discount received by them. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These activities may have the effect of raising or maintaining the market price of the common stock or
preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities,
they may discontinue them at any time. The underwriters may carry out these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, in connection with this offering certain of the underwriters may engage in passive market making transactions in our common stock on the
Nasdaq Global Select Market prior to the pricing and completion of this offering. Passive market making consists of displaying bids on the Nasdaq Global Select Market no higher than the bid prices of independent market makers and making purchases at
prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage of the passive market maker&#146;s average daily trading volume
in the common stock during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence
of these transactions. If passive market making is commenced, it may be discontinued at any time. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other than in the United States, no action has been
taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold,
directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will
result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the
distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future
certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In
addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or
equity securities or loans, and may do so in the future. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the European Economic Area and the United Kingdom
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In relation to each Member State of the European Economic Area and the United Kingdom (each a &#147;Relevant State&#148;), no shares have been
offered or will be offered pursuant to the offering to the public in that Relevant </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">45 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another
Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions
under the Prospectus Regulation: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the
underwriters; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:arial" SIZE="2"><I>provided</I>&nbsp;that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of
the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Company that it is a &#147;qualified
investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will be deemed to
have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on <FONT STYLE="white-space:nowrap">a&nbsp;non-discretionary&nbsp;basis</FONT> on behalf of, nor have they been acquired with a view to
their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent
of the underwriters have been obtained to each such proposed offer or resale. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or
subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in
the United Kingdom </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer
subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article
49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom
within the meaning of the Financial Services and Markets Act 2000. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any person in the United Kingdom that is not a relevant person should not act or rely
on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Canada </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares may be
sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the
Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">46 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies
for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal
advisor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Switzerland </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document
does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the
offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Neither this document nor any other offering or marketing
material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the
Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to
acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in
Hong Kong </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#147;SFO&#148;) of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the
document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (the &#147;CO&#148;) or which do not constitute an offer to the public within the meaning of the CO. No
advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which
are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or
only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Singapore
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each representative has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, each representative has represented and agreed that it has not </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">47 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the
subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription
or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(A)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the
&#147;SFA&#148;)) pursuant to Section&nbsp;274 of the SFA; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(B)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in
accordance with the conditions specified in Section&nbsp;275 of the SFA; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(C)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. Where the shares are subscribed or purchased under Section&nbsp;275 of
the SFA by a relevant person which is: </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(A)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of
which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(B)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited
investor, </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation
or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA
except: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(A)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(B)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">where no consideration is or will be given for the transfer; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(C)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">where the transfer is by operation of law; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(D)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">as specified in Section&nbsp;276(7) of the SFA; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(E)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Japan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold,
directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to
others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in
compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">48 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the United Arab Emirates </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial
Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities
in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and
Commodities Authority or the Dubai Financial Services Authority. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">49 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_13"></A>Legal matters </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Ropes&nbsp;&amp; Gray, LLP, Boston, Massachusetts. Certain legal matters will be passed upon for the underwriters
by Davis Polk&nbsp;&amp; Wardwell LLP. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_14"></A>Experts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The financial statements incorporated in this prospectus by reference from the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 have been
audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated by reference. Such financial statements have been so incorporated in reliance upon the report of such firm
given upon their authority as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_15"></A>Where you can find additional information
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act of 1933, as
amended, with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and
schedules filed therewith. For further information about us and the shares of common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto or incorporated by reference therein. Statements
contained or incorporated by reference in this prospectus regarding the contents of any contract or any other document that is filed or incorporated by reference as an exhibit to the registration statement are not necessarily complete, and each such
statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The SEC also maintains an Internet website that contains reports, proxy statements and other
information about registrants, like us, that file electronically with the SEC. The address of that site is<I> www.sec.gov</I>. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to the
informational requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and, in accordance with the Exchange Act, are required to file reports, proxy and information statements and other information with the SEC. Such
annual, quarterly and special reports, proxy and information statements and other information can be inspected and copied at the locations set forth above. This information is also available on the investor relations section of our website, which is
located at<I> www.beamtx.com</I>. Information on, or accessible through, our website is not part of this prospectus. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom14461_16"></A>Incorporation of certain information by reference </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The SEC allows us to &#147;incorporate by reference&#148; information we have filed with it into our registration statement of which this prospectus is a part, which means that we can disclose important information
to you by referring you to other documents. The information incorporated by reference is considered to be part of this prospectus. We incorporate by reference into this prospectus the documents listed below and any additional documents that we file
with the SEC pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date we file this prospectus and prior to the termination of this offering, except for information &#147;furnished&#148; under Items 2.02, 7.01 or
9.01 on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other information &#147;furnished&#148; to the SEC which is not deemed filed and not incorporated in this prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We hereby incorporate by reference the following documents and information: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1745999/000156459020014308/beam-10k_20191231.htm">Form <FONT STYLE="white-space:nowrap">10-K</FONT>
</A> for the year ended December&nbsp;31, 2019, filed on March&nbsp;30, 2020; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">50 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;for</FONT> the quarter ended March&nbsp;
31, 2020, filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1745999/000156459020024664/beam-10q_20200331.htm">May&nbsp;12, 2020</A> and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
June&nbsp;30, 2020, filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1745999/000156459020039490/beam-10q_20200630.htm">August&nbsp;12, 2020</A>; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502d8k.htm">Form
<FONT STYLE="white-space:nowrap">8-K</FONT></A>, filed on February&nbsp;11, 2020; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the description of our common stock contained in our Registration Statement on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1745999/000119312520021316/d874738d8a12b.htm"><FONT STYLE="white-space:nowrap">Form&nbsp;8-A</FONT></A>,&nbsp;filed with the SEC on January&nbsp;31, 2020, as supplemented by the description of our
common stock contained in Exhibit 4.3 to our Annual Report for the year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;30, 2020, and any amendment or report filed with the SEC for the purpose of updating such description.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will provide to each person, including any beneficial owners, to whom a prospectus is delivered, upon written or oral request of
any such person, a copy of the reports and documents that have been incorporated by reference into this prospectus, at no cost. Any such request should be directed to: Beam Therapeutics Inc., 26 Landsdowne Street Cambridge, MA 02139; Attention:
Investor Relations. These documents are also available on the Investor Relations section of our website, which is located at http://investors.beamtx.com, or as described under &#147;Where You Can Find More Information&#148; above. The reference to
our website address does not constitute incorporation by reference of the information contained on our websites. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any statement in a document
incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein modifies or supersedes such statement. Any
statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement. </FONT></P>
<P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">51 </FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:48px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="6"><B>Beam Therapeutics Inc. </B></FONT></P>
<P STYLE="font-size:43px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g14461g85q17.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:96px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:43px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="5"><B><I>5,000,000 shares of common stock </I></B></FONT></P> <P STYLE="margin-top:43px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="3"><I>Joint bookrunning managers </I></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="5"><B>J.P. Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Jefferies</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Barclays</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:43px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="3"><I>Lead manager </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="4"><B>Wedbush PacGrow</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:48px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:36px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">September 30, 2020 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g14461g07f07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g14461g07f07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1EL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &5"^9( X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   *I0QP"
M4  (<G(S,S,Q-C@< @4 0$UI8W)O<V]F="!7;W)D("T@06-T:79E7S@U,C,S
M.#,X7SA?0F5A;2 M($9O<FT@4RTQ($9O;&QO=RUO;B!!=6< .$))300E
M   0\)KK(>?!"$U1L(])!+R!H3A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  -[   '9          !                          $
M!V0   -[                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   -[     %)G:'1L;VYG   '9     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #>P    !29VAT
M;&]N9P  !V0    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     #K$    !    H    $L   '@  ",H   #I4
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MK^Q6-MX$YM.A,'W5[_W5W%!Z8'U^C],O(K)%GTH]WTTUWV/[6\69#Q8X@&L
M0'$-V['^EZG[K_YU"U[Q!Z+U+G['8.1_3J>1_;_-4&_5KZS/9N9C/>#PYM]1
M'AVO7:N=T\ %V6_:28!K9$CZ7_:97\,UG'9Z#@^L2 Z(D@PYQ#6UM^E_(24^
M>O\ JQ]9RXD8ED=OTU?_ *74Z_JS]8F@^K@76&=(R:V #_MQZ[?(9BG*FRA[
MGR)L;HT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$0L2O-,<LQ-V(6*(X@.[D&T:CS6>S.0&,=EOF6X/F%P/^LBB'$$RSK T2*"
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M.ALKZ28,E(L?>L!43)HGR#R]$S&R1N<Q&O:JBR:W=1=B1<VT(7L[*DJQMIP
M'$='SUJ[T1^:SXLO,#[&]1/FYQ&9/C$]?U5&1NKO'C3T1^:SXLO,#[&]1/FY
MPS)\8GK^JF1NKO'C3T1^:SXLO,#[&]1/FYPS)\8GK^JF1NKO'C3T1^:SXLO,
M#[&]1/FYPS)\8GK^JF1NKO'C3T1^:SXLO,#[&]1/FYQ.=?C5_./A3(W5WCQI
MZ(_-9\67F!]C>HGS<XC,GQB>OZJ96ZN\>-/1'YK/BR\P/L;U$^;G#,GQB?G?
M53(W5WCQIZ(_-9\67F!]C>HGS<XG.OQJ_G'P[!ZJ96ZN\>-/1'YK/BR\P/L;
MU$^;G#.GQB?G'PID;J[QXT]$?FL^++S ^QO43YN<1F3XQ/SOJID;J[QXT]$?
MFL^++S ^QO43YN<,R?&)^=]5,K=7>/&GHC\UGQ9>8'V-ZB?-SAG3CO$OUYOJ
MID;J[QXT]$?FL^++S ^QO43YN<,R?&)Z_JID;J[QXT]$?FL^++S ^QO43YN<
M,R?&)Z_JID;J[QXT]$?FL^++S ^QO43YN<,R?&)Z_JID;J[QXT]$?FL^++S
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M;+B,/'D5V9(T+HBA9&%51 D<$:W5,.(P@!XB/"38(*0;J+PSOG90'=PC,QR
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M5.EO5*UKTL@%8\^2K8]#!NEUG%-(/+7M=W=G'1SPS0O$:JD,EBEC=&CXWM2
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M?H-J_P"*5U5RJ_1*A]5LS3 M9ZK&L'L[V:"##;ZD><+CYEA(JQ^0[GRN>=(
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MY[_3ZY6HQ_)!=)@P&@W%ACE_D%DVYP>TD'*L9JB1UP^ZER*CLQ!>3(N5)!
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M#3;*=3-2(2C\;I[.EF+Q^PSN6J/SBAI;<L&PN(-JZ0J2;MUI50ZCL9WR68@
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M9"!6/9H=S[XSJCJ7'B-WG.4Z>5P]WC&GTQV-:>6Y-T=3Z+X-9P7DU2'IOB;
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MK>:[.C[ SWZ(-J+F0\&):'(FD&D&*5L6/XY $;#77:4E,*VO DL<AC&M38"
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MQ;76+[5\$EF.:Y)SOG:YT+%I'O;@+--*P L TLA !=B:Y5N#87"A ;:A55$
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MEJD9T]XB+N?3+)C^CHAC(VZ.OLE#IT=]I, RE>-L3'(BK16;=T151TU1NF[
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M*LI#*2"#0&]^.A92"""&4E65@;$,K JRD J000"*EY1DU)AN/7.59(<RLHJ
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M<D*(&($K^DN4*F<Y@38JI"EK!K/E$:$W!(Q5RMBY98X#"MCH>>7R@Y0]V!8
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MD>Z%;Y%#3*6-VRBQ$0)&52UT,@=2592%R@%'?)\2USUZNLHJQ)\2K2\4@O\
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M/L1X5<!6D4$>(]T*<@VGR2/+[D<K(B*HF.$%M_A4-C#8S$ND)Q^A$B%*LLE
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M?XT^[!Y3_P --K?]V_L*>FYS7?#?F'^E5_)W#[4[/^]D[_&GW8/*?^&FUO\
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M5S*';OQS#L*O[""Q@?774++_  W#H*-T =H%/5NN[^SK38;"6GEI;NQ>25V
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MEA_#;5;\W_#F?C=U*>-YSON;Y8?PVU6_-_PYGXW=2GC><[[F^6'\-M5OS?\
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MCH*(U^/Y(HQEED==C%A4PGR1T[O-IQ#\OHZY4RE*58K0M*^;MF,D@C)=V"*
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M#K>[J\BM[HL11+FZL,PR0FUR!C)K @22Y,?8+(2ZMDM3FUL4/AA!!Y80HQO
MA #"W21HVC=+*8G22, #*'21I0Y!OF)=V9LUPQ(N.9'DCH:^I;,"2239D1"H
M-^: J( %M:QMZ<F?-+GE]TDR2GJ\?R?#JW)Z2E RP"JJLC9Y:!!=FAT5A>60
MP]CXAD-TLT2QUUU$C+.H%)-&K21H32FRYVT4 E2D$6'1E.5TBAC2) KK9U(2
M..[ YBR*Q-Q>K%R6+$!BTS3L& 9&D9F8ED-T87=[*5( =A:QM6-^BYI:L-8.
M]V:RCTY<TU</-GV6R"BADW59DQ=-$(ZU\*RE,R:EJKTRO9"V,DNO$'F<ZL'B
MKVW5RLD<@"YXF1HSE6RF)X7A %K983AXA$O! IL+NY;)D#))&2Q6565^<06$
MB2I(2P(),HGD,A))8L#[Q,MXQWEUTOQ;-QM0:>JL8,E%(MRF$R7MM,.\FYGO
MY)YB!)"EA)\-!DUO7A0D)(,."\&-89)J>GF JI*($4V4)&@''FQ10P)KQ)$,
M$,=S<E8P?29RUVYQS$"^9VO;6[R23,.P&:660@:9Y&/"P%BL>6O%S+3$)&75
M]-CF+ZBG:F^;-Q86%N+YP$#9=(+%23/.';15\-]F!5^4,X:S:436U,$'@6"-
MD6H4653JJX9L*!>Q,1@7#*C-J6C2$ A-"9H\/-G&X*26+L6+Z9C*DM[7"NDH
MFSH+@+(S#(S:@P23PY;39EIKCE6TY)KA!<?EO,7-#LL2+BMJ^[N''PAXP=HI
M(X0.9+&%XA)M3H+@59'8->^0.44L]82GV%A 9+78J2;6=W-@.<7&(-K] #XA
MWX:^CPM:HL%"VN%C2);DFRHR,.FY/, )O?6][U?'<LVD"U@].S'SH0 XP&A1
MP9#?13AS56*U>'UAHQS;!#XK "II:V4:Q0E366HC+A9W6+GSNE;HSNA*,_2I
MME ? .H0<%53LS!A5'-RQLI!$LF8UW55<EPMR<Q)+YDQT;[PG5RZ[2QF<L;L
M90U\R(5H ^5C2,26UE4+)35NBK"TLX[/,LEL1RLAN&CLN,I<,58O'CR6UB@D
M@,MHHV3^&+-%@[(Q,D7%HV,3[R.RMO(Y+@<&B;",HU]Z7P.%=E-P7BS<9)2Y
MKM;,2;(Z:DZAUQ*<ZUKE4Q<Z(?>(X4<V.,)92.3?0LHZP.(HKR5;2S"M30WY
M;D2ULTU==W^1 Q)7J>HT2#7.37!T)L3&6T$I2I!8QM:B+5246)03:$(L=]2J
MQ!%C%SK91&@ZS8YB=Y+GAQG,I:_NS,S@<,SEBY X#.7<GJ)!7*8XLF78SRXZ
M:X<?26F.19-6'44=:+#./F&1Q.L:RGI\1HZJEN^U81I<TX(&#8PV($])HI'
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M:L(C2+&Q"&.[JZ0DM:RAY<%)CLH-['W"(N#>P$D*NREF*W9"AE#E4W9D(#,
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M6Y%]-0(;16.F0!;6  R(O3/3PZJJ:(S"<7)I:$&.KI:F:DKY*VJKHC*FPB!
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M*,:SQ$W78DMFS$L75E<DDEE=G=@Q)NP9I)"UR;F22_IM=<Z?BLC*.@-&J(C
M< 56*-5(U C3X"VK@-*M-:H/+*ZLP3%:\#.XB8,S##I0!ALHA-8>PN*\AAA9
M'8QD,M+)LS"6R->AY?4B]^3JCWH3WBEF"] 9@JDCJ)5$6_0J*!HH A>8P=>:
MX"@,-& 5F9=>.C,S?E,QXDDV)F@>BC6"QNTLP:=H0=G7BH7CE::L(%Q$3!9A
M-<7!.Y1#(3#(Y1W*Z)&F%HQC?%3]P=;WUNN74WYO/TUX?QCC36SL.#$$-!8
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MN0 X7EE:@-'D]I'/-)%"<.4H=;#,XZ6 Z2"(0G0)=HM3E<8=B"I5_P#2(XY
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M?*<JTT*T_%'M-6\F*AQ')[+#-+<:CS6_=:Y?DF,&UE(<-G^2!&X3AU=G(N3
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MAJM>;:F<[K=I<.KU=UJ];X97*[NRD=2N7'557=^>>;=55>[-+)]7(]7?._\
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M@SK2@##R9+[^103E:YCRRXQ(UA+72\D PL\N:]I9"KY57<QDL9XRQ;<JW.!
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MT<3'R.:U<IYHL-#+B)Y(X8((WEFFE81Q111J7DDED8A8XT12SNQ"JH)) %2
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MK/,(&LN!;]DE-=Q95.>/:.M A7/M:1F/$60S2ER9,BM+2VMC@T7KDNGNEAF
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M\=BLD<>[NEOV$_\ ?W]OL?\ AQ]35TZG0W]RGV/_ '^S_P"/"E.AO[E/^/\
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M&IG&56URN5"$Z!@R227U((RK&05(SYGCLI#%AEDG,#I#$ZS8N: RRU 01Y<
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MS2@;F[S,4OH&"!RY!.EH]U+O"2!'NY,^7(UJW%F(U"9<UM2"Y0(+"Y)<R1A
M 2Y=,@.9;V6?F'T<@+E 7.*V8V*XCHF#"#6ALQED]E\][:Q@=?.ZV#$\U<GC
ML;2K0RJK",<OAK$T4BGL(AH)L&+<T(&+WTR*H8YFOZ*,$<HS65PCE"0K6 @D
M $$M;+^-?*+*>#$%T# 7*LZ*P!90:8/F1T6/'*)$SD&:(0((]R-KKU)R8K$F
MD%KQZT5U2TFWLS9<GQAPM/50F6TP^3XR7&$X3(J:<VS!E+*ZE61BK*PL002K
M"W3D9622U]VZLCY64@ RD*P(*L 5(X$'5;'ASUL\8O>1"'CS*0380>:_14U)
MIW9)*#7-L+RM$M#@"8AKB;'GM=9%40T;)K6YIX:[Q%Z^_KZZ>C&H:ZTM3K$0
M2M-?# !Z0 <H8@L.:IQ&.PUV:^5 )-GS79V5;-'9BQ94@,";"Y)9E  N698<
M'.0@&KL4QT(R*"X;.K*MES;!H]9M,,C3,7T^94Q4. 0%E9:4Z:40*G" .OJL
M^QE.-A&#(JPK/%\DKB;0*<FOA/HK4.0EI )$<<'FJSL"H4D',+$$7XCT@#8A
M3:S$,%N58"006"@@DBXMJ"-.##FFUU)%[@,I-@RDXI3\Q^FE_D.14505;DB8
MA@4VH>69-+4%U^/XU4PVUM4K5W+K-H5T'DBNH;LYU,M,Z8:NK923)!E(!C+D
M@JCR,"JH%-S<E[M*IW84,6R-#(DEAS)%,6LBNJ@0TB1+K(Y891IDL(F7>%K!
M=XL\;QB]VC(DL(V1FI).8N@ HLDOLBP34O&(\;BQTN6NLJ&KM+0^ORB>>"JL
M(8<3OLD'J8F(.\BV$RLK';;'PWCF7U;6C&!R$3E.:).;GEQ,>%RYA9)97"+G
M<<S)F)YRLP8C*MV:-7@L DDFN2.%\1FM8M'&N9LJ'GYK$'*5'$GT4D*83E'.
MCI3B$EE!=U^2AE#7I-)2P&E8+31Y:P"TS&EL[BDL,@S:HJ:^K M,"R@)T>86
M&+7)Y(0L-/3V4MS2QV-4]T R<ZZQ2,HN62.<'<2,+<X3$61(S)*"0KHC:59^
M86S6&4R*#=;.\+*LL8-[*8RZEFEW<9%\DC96 OF:\U^ 83.0*;1Y840-FB8*
MYI;L.P,:6W\SW9L\H>UU:S#3NF(J4JF/'@.AL7I96#7QU$5@*QYC;*K/G  O
M&9[BXN?-SA%DL 23<XR(H+7*!Y#:(!S!('3IDB>]C:TOG&6[6L+##2%R393E
M6^?,J])UY:6 (9R0O'0P: E()919I(4GC;(D<DP)!@4KV([I=(&64*]R*X<B
M>)62O$69EO?*S+>S"Y4D7LP5A>U[,JL.D Z4!S 'A< VN#:XO8E25)' D$CJ
M)%C59Q%37S3YUG.;G^*HBJB+B"*NRJGK\LV7V/\ *O&\ !S7%^''7X776;DB
MUB1Q^BN->M_[IW^DO^_CD6'4/4*I<]9]9IUO_=._TE_W\+#J'J%+GK/K-.M_
M[IW^DO\ OX6'4/4*7/6?6:=;_P!T[_27_?PL.H>H4N>L^LTZW_NG?YU_W\+#
MJ'J%+GK/K-=Q<N',:ZI<!I_GQSEJW+&)CN1%/W6M5$1D%3:S/5%6O79(P37J
MYP;W(.2Y0ECD#X\L=KLH%ND<+=9^H?3IHK7T/'H/7[>W;]%$7=-_L\85>G"E
M.%*<*4X4IPI3A2G"E.%*<*4X4IPI3A2G"E.%*<*4X4IPI3A2G"E.%*<*4X4K
MG3"?VR7,#_$C07^C53A2JGEU_8+4[^4%KK_6/><6;WOY(^FE=!<5I7'&NG-M
M'HGE]QA,VGI627D&%2Z@XZR'(F5@V08M28GJ9E6<V$LSJ,]U5YG,TZ&JRFI'
M8QEV&<8?&^8'RBJ-J,S+,P4$8<.\HS:K#N;X>6UKD3XO_1,O&,@RW<<RM4C#
MRX:(ME\ZDCAC-B29FQ"1RH!T[G#R+BKW&<!XP%*AFT<+]$AK6P:REW>F(M$%
MI>#=25)ECG=E3U^068VK:Z-8N!>WF6Z<XKC..U^8Y6PJ47),9O=1:+'Z^ER)
M,I+J+&H4 J[*56XL3OX8+$JH+2O.&(NV?W*.!IF!0*8SS'8@BL5(9@-0IAEF
M)L20(DB;* MU)=Y1$O/!#VSJH8$=6\OG,=C/,16W=YBP'@Z6N&P,NN,DM!SI
MK2+-]/,:SUT<@\ \; 2J.3(7T!\#234<=6D3))$CT@CNZ9"^MPL\D*G*5SHL
M.&G28!K,JRQXE"JL+K;4W-A1),V4$68PI(PN#D=I<1"\5QHQC?#M=AS6N"NF
MIZ+XSK2G"E6N[&L#*:V$J34K;4JM.'K;%T39V@'SC2Q!FNA<BMF00AT9"Q*F
MTB1]"^IR\*'@;<>BOFWA6C7-[A 42XS8R8L.1YEA990_W9"=2;?*,II,:SJ#
M)]1@,KU6PO*@\:HLRRZTP*>]QX*B2WEQ[&K(\((&X*\CV$Z:VOX>([:BQ\;?
M7?I-[_(+5-M<"Y\[4RJN),GJ0+K'L6FQL<T&[QF5A5E8W&"19)E(]-)CX5*=
M-95-+D1=&#?10.KO$PPPD4!9T[AH&518G,U[YB+<22%&M[ $KUGCI36QZ"1H
M-#;4:@]-P._C6YL%Q_FW"T"S1F;9D):Z_P!J(.S')(78='04$T5/2C$S5"!X
ML'73$SV2W]C&/?-+%(*\ )XNEKY%D$B_/86(0'FGI*V'$D\;DCY!<ZDBAO;2
MQ(L-=+VT)^4ZD<!?J%:O&PSZ(&VFJIS-2@9;B-M-5WX K=-X8BZ<44=^27%'
M//@Y+!,WM9!)Q:(BPFGQ<,FP9.?2M'9*Z&W-UL#U@D]-DT/#FCG\+&]C>UQ3
M7K''NUO;CK:W&^O6.'7'+[BV9X5H_A.,:A&SV.9U0)L=\<5:MNR"22+>Q,B?
M-:QP"1&2H*3 R22$06!KFK' /#"QD;98@L2!8&WKL+\.LWJ$!50I-R!:]R>\
MDD_.2>LDZUMLX.&P#* )1SAS!Y12&LDEA>Z&=CHI6LEA?'-$YT;G-;+#)'+&
MJH^-[7HCDS90ZE6O9@0;$J;$6-F4AE-CH5((X@@U<$J01Q!!%P"+@W%P;@_(
M00>FN8S.4?3FQAM6V5[G5B==UQE);7!MS636=GC\]5Y+$H[-_D1HEJ+6I&&:
MP^U$.OKDD& ?*[C(:N4ZN,T#,#<9;YBY.1;&0S829GR6W8+/@<."@0195<;O
MW1KUL.K0+D NVB;K$Q90U\_H8N>SEC(K,I5P43+@^6\EU*NG[\&TQRX["I+'
M)+^WN+VR#?<&+7Y?19A0Y0!4"TYV+UU<P\?,K!T8SA":T6&.,:L#JB8JRTJJ
MW],:Y) ZR*"<SHXP=T9W+,R_Z!ASSBS-(BO(S@.DA5"V;TG7(8V:UE=!.%8*
MH4 _Z3,#:RA'9%5;J5SH;E TA@S2USJ:&^.M;DS*2[ 4FP$CKRF9C49C2W0A
M7@JX2Q.A>)GF3M#(L;$NR B-$KA3XZ:GIJRO$G+.E[#$1K'):X(59&E7(5(R
MMG8DL!G:UV8L2Q6]TP\M^=A6+Q<" Q2.,D@C7FQK9?1!+6 !M64XSR\XEC!%
MT;%?9E<'9'2Y'17YMY:@F$VPN2Q44!$Y+H*H1D1E?!0"P5<@<8L,,1)C28"^
MH519<[R-XF RR1B-[#*3[OC<06TLH9I=H8DG*JK9E4* B (QNI$E7TXY!(E]
M0MH<) %ZRN[P.&'.)8E"2Q+O?%[#E,P"[$(CR;(<URJU(QH/#DR'("<8,/BQ
MBL/&M*FC\E18L-B!5;7'P3$H+88R9%9K8'Q7K;8>6**"6=G9W) :0.'( Y^\
MF@G)(;, P?#1Y"H41W9HPCMGJ%4*$&I$;*R ^]*Q30BUK:%)VSWN7*QYRP0"
ML=$Y&]#JX6P$K!+H*,\2D$61TE'8DQK3&X_8/F)+N*&Q)OO*IF,5!!X&4RWU
M0(1 \K'ZVC+FEG=!9CEN2<KNXU(_C!.'5B"&?,,3,=Y(SS*S(ZRAHHBD\ P!
ML61$8V!)W>ZR, 054J((ERHJQ%%*-&4DD#VJ/D$T%8( *X?(24IQ,<"I9CY\
M?LY:Z#&L?+Q45T[;''"A\C)GQ^PL*UAN7P9$;10F/7$",;?"*X=<ZBX ;T@
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MXYEP^SGV@2@]\"NZ7,; JSNF=4!:R*7L%!+.$*"Z@$OC#@P&);0[Q)=+$C*
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M8/AY8ERY9F)D?>NUR2TA;.7)-^<6YQ/2=>-0  JJ  J($1;#*J $!5' * 2
M!P!(&E4)&@>BA0S@B-+,#F"=-&1X.3%Z=PK)HQ @&OB'\'V8=P*X,)[(F,9*
M' @LK7CODC?()#9P3FN#FN0>:^(D6]N-I,5B7'XT\AXN29&BA1Z(! '4"L*$
M#JNF&PZGK6&,<$%LXIL-Q7'3";"CH*FI--BE@+* !&%G)AGN[O))HII((F.?
M'+D&27]R]BKTNLKBQ+5.\7,]\#2]K\[)?MW88)?KRAF"WO8,P&AJ+#30:9K=
MF<J6M^454GK(%^%9+PJ:<*4X4IPI3A2G"E<,<TNDNH6H.88_9X?CLER"#C:
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ML>U2HW5<#G*]9ST59%EZ6V!;6=2SN(5O2DR-[?4Y8^WMT=A&P;=IJ,12H?)
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MDA\1^&7N09%0$+).?(^11[+*;[Q4<BNAL@K"2ML8R0&L&: LQ8$@E0I[5!)
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9*4X4IPI3A2G"E.%*<*4X4IPI3A2G"E?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g14461g85q17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g14461g85q17.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1J<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "<< 5H  QLE1QP"   "   < @4 $T)E86U,;V=O7T-O;&]R7T--64L
M.$))300E       0EW+H'L<4Q=MUY&Y\K:W%)3A"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \
M   !  (#P     $  CA"24T$)@      #@             _@   .$))300-
M       $    'CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              2P   )J
M  $                          0             ":@   2P
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   2P     4F=H
M=&QO;F<   )J    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   $L     %)G:'1L;VYG   ":@    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 3@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %^24DJ
M  @    ,   ! P !    L 0   $! P !    <P(   (! P #    G@    8!
M P !     @   !(! P !     0   !4! P !     P   !H!!0 !    I
M !L!!0 !    K    "@! P !     @   #$! @ >    M    #(! @ 4
MT@   &F'!  !    Z    " !   (  @ " # QBT $"<  ,#&+0 0)P  061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR-" Q,3HU,3HQ
M,P    0  ) '  0    P,C(Q : #  $   #__P   J $  $   !J @   Z $
M  $    L 0          !@ # 0,  0    8    : 04  0   &X!   ; 04
M 0   '8!   H 0,  0    (    ! @0  0   'X!   " @0  0
M    2     $   !(     0   #A"24T#_0      "           _^$!@$E)
M*@ (    #    0,  0   + $   ! 0,  0   ',"   " 0,  P   )X    &
M 0,  0    (    2 0,  0         5 0,  0    ,    : 04  0   *0
M   ; 04  0   *P    H 0,  0    (    Q 0( '@   +0    R 0( %
M -(   !IAP0  0   .@    @ 0  "  (  @ P ,   $   #  P   0   $%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C0@,3$Z-3$Z
M,3,    $  "0!P $    ,#(R,0&@ P !    __\   *@!  !    :@(   .@
M!  !    + $           8  P$#  $    &    &@$%  $   !N 0  &P$%
M  $   !V 0  * $#  $    "     0($  $   !^ 0   @($  $
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M  (" P$!              $# @0%!@<("?_$ #\1  $# P$#"@4"! 0' 0
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MYN$_(>CI2^_+;BI4M,AHI80\@DAW1(^U_N![C\JROXS[N>)>0*J1'^.#2\T
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M:;)CI,^SL#1X4(#7/8UQI)QC17(BN\N1%VO^S_I^]5'Y_$>_*K:W^RI[8/\
M2/X%_P!<''O]8NM;!ZCY&K:Q)W=QVIUL4LV?W,]O\2*!BO*<_,?'@QL:U/*_
M==%]W+X_2UJ*YR^&M155$Z;JNH^1IG'&JYOK'=_?$'<I08'MVX!M7\BPJ/=Q
M=KIMG3PIJTTV^C5%UFJ#*Y53QQ2="8GYBGRY]A C$KB%2IB5,RQ*6>R)>T@I
M)4H8TT^YJM9SH-?7RJ<'TS> =/VW=FW%?'VXA$J]Q.9>;;6U!E3YJ6TV-Q*M
MXU)*:BN:*PIZ0M36VPF.>P=M%G-&][$:]U3A"EDCA^!BLTC  KF/4.]0W%]C
MF+K8\>NB[3F?:Q9)<+A2R7@@Q8('OCGU^O-'>V7$S<26U8D6+%<.QT-BPL"O
M+%CQ+:UJB$%9Z@.)^P[:$XJ!?'N]8KU$$-NLMM.1\QQO;2I+8%O5[(O!7%OP
MA.X:PJ*)13*NZU]?!.PL1;(,/7&')C&C6-L2='(UMQYIO0@$_P#L?'H'I5?Q
MJUX>8%=!H^VGUI^TZ ;>9WDOE/;TU*$EE9BPO+UMRY!AACM4A32^-]J\\FZ:
M,8U<9(&/N&C#[GE]@FO<UO,JP" .CACPR.'OKJ<+'3G7H/Y]?6I._3']5-.[
M&R7A+FR#39OG2)6RK#/7%,/\.SO)E=5@0UFR-6'D&?4;&NB,-9SZF(0M=95L
M:?:5@JX4&36QZW&]S4:I]16259TX'ZU,]8V$"HKYUK:S8M;65D.3865C..*+
M"@0(07R9DV9),Y@8T6+'$0\@Y7L$$3'D(YK&JJ55E56GNT]9CG+EKD4O#G8S
M6V-/1RK=<]1[*KROYIY2Y)L4(4'OR&?F0;0%%3V'ASJP#:2;K),=@;%\JA*0
MU7'V$M #>7Y9P!W].:K*CP3KV\?*DUKNV?UUM#$38IL^XF!(*B3(]38]SU?0
MSBM=^MK?RL7DJ)"@>?\ *KK"'!<S[C+%8OEG4[S(TP/_ %/UQGRIA?LBEE[?
M_5%[L^UKD^%P/ZA>;TB4EHUL6/M]5G05&[R YJ_1U^C_ !*G &DY$P\>8U[;
M*TA#LK82-FRXE[:EKOP,\*;2H%39\!^.(/8:!1&BO ^/3[^M;[T7>[#N/YX[
MF^0\IS#S'M^0\W6\':#0U]-I;3ZV#$NHV^XZKH]D$7QL]LH4&TL(K">5\!EF
M;_E=0\E*0, #6B%$G4]%2(^L5S'RAP=VEUNSXDV]_@-4;E['4C[W.2_HK!]5
M.I-=(F0'&]C_ /:\@T&*0C/'ZG &OG]/6#0!7@C(P:R42!IQ]^^FH6\5ZF??
M1S+P]Q)VP=NR[?;<_P P&RG\E\H!K8N@WME&D[;02J.MIIU@(E-FJ.FR<NC#
M=[2U9&)#(2)!AV%)] 298W%M )4K1.F!T<->TZ]'?I6(42 !J=<^^%:G9<%>
MMUP_62N5KC6=RLZ/6QWVUS^7^?R<C2H$>.U3%6PQ%1N] 2RB1AM<0T>'16D&
M,!CWF8..QSD!3)TPD=Z<>N/KBF%\??EPIZ?9EZV\8G$?)L3NT?'L.0N+\@[3
MX_04,.!3S>86)85](')%K ?3U43<K;6U<1LJIA1*F3GEM;J575X\U92I^"VM
M1N\"<=W[5*59&O$?>F:@Y[]6KU'=#H+[@V3R)E>/H%B2".OXITX^(L%G/V;'
M_@TK?2[G-V.KN6131Y%I%DZ"VG-64.4&GJZZ3&BCSW6F^.I[=3Y<!6.5*X9
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M'E3<:&X;;5F)S$&S;^3MQ.]L^+30P2T^MC9Z1'E^#L>GU()!PF_O@RD8Y'K
M4  ">@=!ZJRW2>C/=C%9W#-E^)]NNNLQ23G'*F<R2HD@WU S+&)?Z8L1WMD(
MR2!6A<-&B(P9 (B#48W,]J2#\)(_S'U-8])]XT]_6D$X\=VF&P>-+KX^AD:H
MF9I'Z(S(_-)6%NG5T=UD1I:I'5A&NEJ5R/@*L-R+YCJHO;U 4, $_7IUK+!Q
MG QVA.?'MIQ'<!!SZ\>\64ZN=&Q\GD_BZHD-+/GP&_E<YB12@E6!),>Q %:Q
M?:>0>4.4-$4I3-,U7I)X>*?J/$5B/S]*2OE7.\4<=4=;H>%=#^&<I,T>?BY*
MHSF[N='(U4B7;0XTVAGT,J\MQ3ZL\ L@LI71A-&X0D>?P3X#XG U2=>C!XZ]
M7L5EJ="-.G0#\<,]-.QY5W;.../]#K7";)L(4)L>EKONY]GHK$C(%)6C&W]H
M59-G(CL(T2.>D=#%1/ U5,R<#/EVD\!6-(3P]3WW"^VK>/M3<S+B-RGFFZR-
M8SY#SH+E"HCB_/5/$(]SOV%E7DBW$)KE1597RFC;^AWG%.AP<Z@>>N1]ZDZ\
M/+'1T$_2MUS[34NDWG F>TJ.+G;;3;,=M&_$IM4*0.+C9DV,TTR!+A21M'-C
MQR-]DD?N>U&+[FO<QTGBGQ^E <9[ON*Y#4YC%<4;/B4W$5G+K-'I>0:C/7.4
MA:RYOX6CQTP<IVBF6-/9VUH@V44<3)H+1C0MAE_EN<]PE'!T(QQ)U[1ZG&GA
M3CGSX#]O3R-:OF(O%B]PR1^7$LC4"<.TAJJ/ ;M2HVW79Z1CS.%C/,I/,-",
M4DMOP+X:U%^3V)U)("M3T:=7'7W^U2 3PU(X\.G&./OSI8N$(_""GT4KB"-9
M!,,5:"]?8,WP?(S/FD@-$S:JC'JKP2U>ZO:KV>&I)<U'A1T@@\/O[\J@@CB/
MI]J].W60>1D=:^08QW,Y9Y/$QQB/*YHA:N<P0VN>YRM&-J(T;$5&L:B-:B(G
MCH/N?J:'[#Z"O#%1 WO)O<M1VWS3*F9986M-#?)DC']#8<;UHYH /"498J2&
ME*KWQ2!(CWJ1KVD\.2!C*O#/=@?O4G.$^.._)_:DIO.#^,(O.F!R<?.''GK?
M![>VL:U-'J5')L*NQSH8$EQG7:R6.C#F2FM8(S!/^95*-[FL5K WL:\,\3UX
MSUYXCNJ.@G3B.@=O9V4H7,=%5XO"\8Y_,@+5U,'F?C$$:*R;.D.8&7KVR9(G
MRIDF1+,PQCE<]ISD3P_XT\#:UB#ICO';T]?O32@Z>X^_/A6UY2D7&NY Q/#M
M==V>;IKNDT&RVUE22GU]W.S])(KZR'GJVR%^WKQVUG9M=:R8JBEI!BJ )F,.
M9KQU(3KKQ/V_/[T[>HC[_BMK4=O?'.8N*F^QPM%D+.LFAE2#4FJOG"OH[%\F
MJ]%$MIUG$M*^6OM60A0-E^YC'AEA<U%Z;HSG7/>=>PU'&DPY;SD2?RN.SY7S
M.QV'$8LE"#G(N;A7]YGZ/3MGR7W,[4Y_,/?;%D&B?2-@V)(,RN''50D3YAHZ
M/!XZC(Z,9X\-1UZ_C6IZ.W/'WICC]Z4#A.!P_%/HR\/Z222L*D%EKB4M;)]?
MGIS%D.;8!SE^-MW02K,;OAD([Z>%+;#&@XR%CO<DIQT</'[T.>GC2_=95%'2
ME'2E'2E)%S3CKO;Y6HJ: 0#3(>ZPM\=LB0R,Q*ZATL"SL7M(3[.(R)'(X0D_
M45Z(QOW7J""<8ZP3W5((&<]1 [Z[[65\FWRVEJH36NF6=!<U\1KWH-CI,VND
MQ@->1WZ6-4I&(YZ_9J>57[)U)U!'745I.+Z&QRO&V!S-NP8[7/X[.4UD,)6G
M"R=6U$2'*8(S/T%&TX7HPC?TO:B.3[+U T '92N X^P.CSG$>JR%F",V[M9_
M)TF&$,L1@O'J+J]G5'ND(J"&XL>?&4R.5$ YSFO5/8O4 :$=_=J33]OH/O[Z
M:X_!V?/N*Q63R"\)5%BN8SM/0K/3E*EB_6_A4 $+ZKZ;\'/\'S_#\GP_,7X_
M=[?D?X]RP-X #=SC_,*G3K]-?K]_V[3E#&Z+DO)<=Q)=!6AF1=_@-1K\].GQ
M+*!%JJR4LC15RR2!9%N6"$4L9!I':.P9[D02,>K>LCJ.'5D>(S45J]#Q!^5-
M;2\E<.9[-UEY"8.FT^1#%KZ.FU69.;]N^(\$5D:HTU8KUD0+-C1-F!:2OL'%
MCN8SJ,8.1XCS]:GCQ-9G*7&E[RKK<36V$NQHN/<P*3K)D^DMQU^BD[@3DB9V
M/$()IRPV4@"S+)9XT5KY!AB"_P![$(P1DCH''CT_MQSK4?7TKD=QV]6CJN+>
M8_?\D7FYR5K7:;'1-QN9EU0.N*V2-[X\J/,![!-L:YTVL>=I!^T<QS2N<!Q6
M.%.FF<C&-?S4Y[O(=/<*[#E'C(O)NBX?D76?J[3,Y^UT%ALJ:V+&DA8*QRYX
MD$" =[AV#H]RL?RH?+6J%)"+[43H1DCJ&<^5!T^GF*[W*\5\;8>86PR&&S&=
ML#A6.6?54\.+.='<J.='^L8+ZEH'N:USPM(@WN:USVJK6JD@ < !W#%126Z^
MIY.H^:2\A8O#0-I53N,JO'''*UM=F219\347-R5Z)+BS2'9]/*BM14"QBN*[
MP15&YO4'(.0,Z8XXZ34]&#IKW]7X_M2CXG1<DW,Z6':\<0<7!%$0L2;%VE?I
MGRY?S#8L5T6)70WQVH%Q#?4.>]JJQ!^WRY%203TC'CFHI+:ZGY8XDNM?#QV*
MK>2<5J]/:Z^H$/50,O>9BTOWLE7%;/;;QW0Y].ZP^65!/"*^:%IBL.(GEC61
MJ"<#(.O'7-3H>G'G^_OJQ7>\3XS2Y]=AJMN:L=M.0KX-Y<PZ4AC5-+#KZR)3
M4='#DR!B+-6OKHC?JIKA"21*,5&-<,;"D)&,D\3J?M45]W./NIO-.'VX! 6A
MHL3L:.P,Z0QLAEA=3Z&1!8.,O[0HWCKY*D*W](U:U'?=Z=3T^!^WXJ>C':/O
M^:_>8,A=;*HR,.C$ IZ?DO!Z>:DB0R.UE307@9]B0;G_ &(9D=CE$%OZRN\-
M;]^A&<=X/OZU&<?2L/E#!Z:WN,GO^/IM7#WF)6RCQHEZLEE%I<]=#"RWSMJ:
M&PDF*I"18LRMGC$;Z.8#RX2M,X@H(.A'$>O9[]*D=O[^_?56'5:/GJ[MJB+*
MXVR>&J03HQ-';6^S9J3S*YCT69%S==11(CAS)#/+8\RXD!!'1?>2*9R?&KXM
M- .O7/5[]ZM.L^6.SM[]./761L)O-F<U9K?(T=%R+BI\&$%<F6UAY/1T%E&^
M5LB97V\P!*ZU@V"/:20"P*R2 K!#B((+"N..\-1J.KI]^\5&E:'$Y/?WW)]A
MRONJ&HPG^XE<14YFINAWMS( 6[BW1K/0W$.."O>\#X;(U=%B+(08I$A2/$YO
4[< <Y.FF,<:DXX YZ>&/WZZ__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
